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"Philosophy is like being in a dark room and looking for a black cat. 
Metaphysics is like being in a dark room and looking for a black cat that 
isn't there. 
Theology is like being in a dark room and looking for a black cat that isn't 
there, and shouting "I found it!" 
Science is like being in a dark room and looking for a switch. The light will 
reveal a cat... if there is one." 
 
[The Black cat analogy] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Remember to remember. 
Remember to believe. 
Remember to live. 
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ABSTRACT 
 
The gut microbiota (GM) is essential for human health and contributes to 
several diseases; indeed it can be considered an extension of the self and, 
together with the genetic makeup, determines the physiology of an 
organism.  
In this thesis has been studied the peripheral immune system reconstitution 
in pediatric patients undergoing allogeneic hematopoietic stem cell 
transplantation (aHSCT) in the early phase; in parallel, have been also 
explored the gut microbiota variations as one of the of primary factors in 
governing the fate of the immunological recovery, predisposing or protecting 
from complications such as the onset of acute graft-versus-host disease 
(GvHD). 
Has been demonstrated, to our knowledge for the first time, that aHSCT in 
pediatric patients is associated to a profound modification of the GM 
ecosystem with a disruption of its mutualistic asset. aGvHD and non-aGvHD 
subjects showed differences in the process of GM recovery, in members 
abundance of the phylum Bacteroidetes, and in propionate fecal 
concentration; the latter are higher in the pre-HSCT composition of non-
GvHD subjects than GvHD ones.  
Short-chain fatty acids (SCFAs), such as acetate, butyrate and propionate, 
are end-products of microbial fermentation of macronutrients and distribute 
systemically from the gut to blood. For this reason, has been studied their 
effect in vitro on human DCs, the key regulators of our immune system and 
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the main player of aGvHD onset. Has been observed that propionate and, 
particularly, butyrate show a strong and direct immunomodulatory activity on 
DCs reducing inflammatory markers such as chemokines and interleukins. 
This study, with the needed caution, suggests that the pre-existing GM 
structure can be protective against aGvHD onset, exerting its protective role 
through SCFAs. They, indeed, may regulate cell traffic within secondary 
lymphoid tissues, influence T cell development during antigen recognition, 
and, thus, directly shape the immune system. 
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1. Gut microbiota 
1.1. General overview 
 
Human beings have been recently reconsidered as super-organisms in co-
evolution with an immense microbial community living in the gastrointestinal 
tract (GIT), the human intestinal microbiota  (Gill, Pop, Deboy, & al., 2006)  
(Ley, Hamady, Lozupone, & al, 2008). With a concentration of 1012 CFU/g of 
intestinal content, the human intestinal microbiota probably represent one of 
the most dense, biodiverse and rapidly evolving bacterial ecosystem on Earth  
(Ley, Hamady, Lozupone, & al, 2008). 
The gut microbiota can be considered an extension of the self and, together 
with the genetic makeup, determines the physiology of an organism. For 
example, two supposedly genetically identical organisms, such as same-sex 
inbred mice, can have widely different metabolic and inflammatory responses 
depending on the makeup of their microbiota. The intestinal microbiota is 
derived at least in part from the mother during the birthing process and is 
modified thereafter by factors such as diet, antibiotic use, host genetics and 
other environmental factors. Whereas microbes in the gut were once 
considered only harmful or pathogenic, it is now clear that commensal 
bacteria accomplish many beneficial functions, such as vitamin synthesis, the 
digestion of dietary fiber and the regulation of inflammatory responses. 
Microbes and vertebrates have evolved together over the millennia, so 
normal functioning of the digestive and immune systems depends on the 
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presence of nonpathogenic „beneficial‟ bacteria (symbionts). As just 
mentioned, its collective genome provides functional features that humans 
have not evolved by their own, and several of our metabolic, physiological 
and immunological features depend on the mutualistic association with our 
intestinal microbial community (Neish, 2009) (Lee & Marzamian, 2010). In 
fact, the intestinal microbiota enhances our digestive efficiency by degrading 
otherwise indigestible polysaccharides and also represents a fundamental 
barrier against GIT colonization by enteropathogens and their invasion with a 
higly dynamic modality. 
Further, the crosstalk between the immune system (IS) and the GIT 
microbial community is essential for the development, education and 
functionality of our immune system (Garrett, Gordon, & Glimcher, 2010) 
(Hooper & Macpherson, 2010) (Figure 1). 
The interaction between intestinal microbiota and human host is dynamic 
and pivlotal for the ultrastructural development of the gastrointestinal tract  
(Round & Marzmanian, 2009). This dynamism consists in a predisposition to 
adaptation, which guarantees rapid variations of microbial community and 
metabolic functions in response to diet and habits, and, it represents an 
essential component  for the education of the immune system to 
homeostasis  (Candela, Biagi, Maccaferri, & al., 2012). 
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Figure 1: Crosstalk scheme illustrating the interactions between GM and immune system 
(Modified by  Brestoff & Artis, 2013). 
 
 
1.1.1. GM composition 
 
Gut microbiota is composed by an amongous taxonomic diversity at species 
level and more than 1000 different bacterial species have already been 
identified in the human GIT (Garrett, Gordon, & Glimcher, 2010)  
(Turnbaugh, Ley, Hamady, & al, 2007) even if the intestinal microbiota 
reveals a relatively low biodiversity, at the higher phylogenetic level, with 
only 6 of 90-100 bacterial phyla present  (Peterson, Frank, Pace, & al, 2008).  
The total diversity of a healthy human gut ecosystem is generally reported 
around 1.000-1.200 species-level phylogenetic types, named "phylotypes", 
defined as group of 16S sequences with a certain level (97-99%) of similarity  
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(Eckburg, Bik, Bernstein, & al., 2005) (Rajilic-Stojanovic, Smidt, & de Vos, 
2007)  (Xu, Mahowald, Ley, & al, 2007). Only a small percentage of the gut 
inhabitants correspond to fully characterized bacterial isolates, whereas 75-
82% is estimated to remain uncultured  (Eckburg, Bik, Bernstein, & al., 
2005) (Rajilic-Stojanovic, Smidt, & de Vos, 2007)  (Flint, Duncan, Scott, & 
al., 2007). 
The vast majority of the bacterial inhabitants belongs to the dominant (50-
80%) Firmicutes and Bacteroidetes, that arrange more than 90% of the gut 
bacterial community. All the other phyla such as Actinobacteria (3-15%) and 
Proteobacteria (1-20%) are generally well-conserved at a lower relative 
abundance, whereas Verrucomicobia (0.1%) and Fusobacteria are present 
only in some individuals  (Eckburg, Bik, Bernstein, & al., 2005)  (Frank, St 
Amand, Feldman, & al., 2007)  (Costello, Lauber, Hamady, & al., 2009)  
(Muegge, Kuczynki, Knights, & al, 2011). In particular, the procaryotic phyla 
Fusobacteria, Cyanobacteria, Spyrochaetes, and Lentishaerae, as well as 
several eukaryotic fungal species (Candida, Aspergillus and Penicillium), were 
also reported as gut inhabitants in very small percentages  (Rajilic-
Stojanovic, Smidt, & de Vos, 2007). Furthermore, at lower taxonomic levels, 
each healthy human being has a peculiar subset of hundreds of species and 
no phylotype of the individual microbiota is present more than 0.5% and the 
70% of the phylotypes are subject-specific  (Turnbaugh, Hamady, & 
Yatsunenko, 2009).  
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1.1.2. Plasticity of GM  
 
The human gut microbiota shows an astonishing individual variability, and it 
is considered as unique as a fingerprint in terms of species and strains 
composition  (Eckburg, Bik, Bernstein, & al., 2005)  (Lay, Rigottier-Gois, 
Holmstrøm, & al., 2005). Geographic origin, age, diet, and lifestyle influence 
the composition of the gut microbiota but also the impact of genotype may 
also be significant in shaping the gut bacterial ecosystem (Lay, Rigottier-
Gois, Holmstrøm, & al., 2005)  (Khachatryan, Ktsoyan, Manukyan, & al., 
2008)  (Zoetendal, Akkermans, Akkermans-van Vlietal, & al, 2001). Despite 
the remarkable host specificity in the gut community, a high degree of 
conservation in functions and metabolites has been reported (Mahowald, 
Rey, Seedorf, & al., 2009). This suggests that the gut microbiota may be 
characterized by a marked "functional redudancy" to ensure that the key 
functions of the microbial community remain unaffected by the individual 
variability in terms of species composition  (Gill, Pop, Deboy, & al., 2006). 
The existence of a "human core gut microbiome", defined as those genes 
which are common to the gut microbiomes of all or the majority of humans, 
has been hypothesized to be responsible for the functional stability of the gut 
microbiota  (Turnbaugh P. a., 2009). In the other hand, a "human core gut 
microbiota", defined as a number of species which are commons to all 
humans, could hardly be defined, since different combinations of species 
could fulfil the same functional roles  (Turnbaugh & Gordon, 2009)  (Tschop, 
Hugenholtz, & Karp, 2009). 
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Aside the core, the set of genes which are present in smaller subsets of 
human constitutes the "human variable microbiome". This large wide change 
from the core is the result of a combination of host-specific factors, such as 
genotype, host pathologies, lifestyle, diet, environment, genotype, and the 
presence of transient populations of microorganisms that cannot persistently 
colonize the human gut. in the end, variable and core components of the 
human microbiome influence different aspects of the human health, including 
immunity, health status and nutrient responsiveness (Turnbaugh, Ley, 
Hamady, & al, 2007).  
The ecological disorder of the bacterial community is called "dysbiosis", and 
affects the structure of the microbiota at the level of order/phylum.  
Several papers have shown how changes in the relative proportion of 
Firmicutes and Bacteroidetes are detected in metabolic disorders such as 
obesity  (Ley, Turnbaugh, Klein, & al., 2006)  (Turnbaugh, Hamady, & 
Yatsunenko, A core gut microbiome in obese and lean twins, 2009)  
(Turnbaugh & Gordon, The core gut microbiome, energy balance and 
obesity, 2009), type I diabetes  (Wen, Ley, Volchkov, & al, 2008) and 
inflammatory disease (IBD)  (Frank, St Amand, Feldman, & al., 2007)  
(Sartor, 2008). Bacterial overgrowth and imbalanced microbiota are also 
linked to the irritable bowel syndrome (IBS)  (Othman, Aguero, & Lin, 2008). 
As just explained, the human microbiota is involved in various and different 
aspects of human physiology and disease and represents a new frontier of 
human biology and medicine.  
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Figure 2: The concept of a core human microbiome. The core human microbiome (red) is 
the set of genes present in a given habitat in all or the vast majority of humans. The 
variable human microbiome (blue) is the set of genes present in a given habitat in a smaller 
subset of humans  (Turnbaugh, Ley, Hamady, & al, 2007).  
 
 
1.1.3. Dietary influences on GM composition and metabolites 
production  
 
Mechanisms by which dietary, bacterial, and primary metabolites interact 
with the immune system have been largely discussed and topic of many 
papers along this last decade. Many of the food traditionally considered 
healthy, such as fibers, fish, vegetal olis, and other elements of the 
Mediterranean diet, have been connected to a better lifestyle and healthy 
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conditions because positively linked to molecular pathways that promote gut 
health and immune tolerance.  
The nutritional change that has occurred in the Western world over the past 
few decades and the "Westernization" of many countries coincide with the 
increase in certain autoimmune diseases, asthma and allergy  (Eder, Ege, 
von Mutius, & al., 2006). Indeed, the change in dietary habits and the 
correlation with disease are particularly evident in epidemiological studies 
correlating fibers and fat intake. Notably, rural Africans consume more fiber 
than Western individuals and rarely suffer from allergies, asthma, or colon 
cancer  (Schnorr, Candela, Rampelli, & al, 2014). It is also well known that 
high intake of dietary fiber correlates with a lower risk of death from several 
conditions such as cardiovascular disease, infections and cancers  (Park, 
Subar, Hollenbeck, & al, 2011). 
Western individuals are used to eat an obesogenic diet characterized by 
energy-dense processed food and low comsumption of nutrient-rich foods, 
such as vegetables and fruits. Clearly, a bad food intake influences and 
strongly modifies our microbiota composition depriving ourselves from 
protective factors. A dietary basis for inflammatory diseases is most likely 
explained by interactions between dietary or bacterial metabolites and 
immune cells, or pathways for gut homeostasis.  
 
The current findings leading the scientific community to focus on bacterial 
metabolites that actively play protective roles such as short-chain fatty acids 
(SCFAs), -3 fatty acids, and those derived from tryptophan catabolism. 
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Interestingly, only few bacterial species and their metabolites are already 
known for showing strong anti-inflammatory effects such as Faecalibacterium 
prausnitzii that, together with its metabolite (butyrate) inhibits NF-B  (Sokol, 
Pigneur, Watterlot, & al, 2008).  
The major metabolites produced by bacteria in the gut are SCFAs. As more 
dietary fibers are ingested their production increases. An exhaustive example 
of the correlation between diet and SCFAs production has been provided by a 
study focused on the differences between the fecal microbiota of European 
children and rural African children. African children showed higher bacterial 
richness and a significant enrichment of bacteria from the genera Prevotella 
and Xylanibacter (that are efficient at digesting fibers and producting SCFAs), 
whereas these bacteria were absent from the European children  (De Filippo, 
Cavalieri, Di Paola, & al., 2010). Notably, the microbiota composition of rural 
Africans is also different from that of African Americans because of an higher 
proportion of Prevotella and lower proportion of Bacteroides, associated with 
a higher production of SCFAs, such as butyrate (Ou, Carbonero, Zoetendal, & 
al., 2013). 
 
1.2. Short-chain fatty acids 
Humans lack the enzymes to degrade the bulk of dietary fibers therefore 
these nondigestible carbohydrates pass the upper gastrointestinal tract 
unaffected and are fermented in the cecum and the large intestine by the 
anaerobic cecal and colonic microbiota. Fermentation results in multiple 
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groups of metabolites of which SCFAs are the major group (Roy, Kien, 
Bouthillier, & al., 2006), required to balance redox equivalent production in 
the anaerobic enviroment of the gut  (Van Hoek, Merks, & Merks, 2012). 
SCFAs are saturated aliphatic organic acids that consists of one to six 
carbons in lenght and are produced in the colon by bacterial fermentation of 
plant-derived nondigestible polysaccharides, such as cellulose  (Cummings & 
Macfarlane, 1991)  (Wong, de Souza, Kendall, & al, 2006); the most 
abundant (>95%) are acetate (C2), proprionate (C3) and butyrate (C4) and 
they are present in an approximate molar ratio of 60:20:20 in the colon and 
in the stool  (Cummings, Pomare, Branch, & al., 1987). 
The molecular mechanisms by which metabolites such as SCFAs, long chain 
fatty acids and tryptophan metabolites play a major role in the prevention of 
inflammatory disease and how they show a role in the interplay between 
diet, gut microbiota and regulation of host energy metabolism is target of a 
new active field of research.   
The future phase of research might explain some of the dietary and 
microbiota-related associations with human disease and involves the 
identification of specific bacterial metabolites that could be associated with or 
could protect against human diseases. 
It is important to consider when dietary metabolites influence the immune 
response and where they intersect with the immune system at different 
levels (gastrointestinal tract (GI), blood and fetal enviroment). Originally, the 
gut was considered the primary site where dietary metabolites exhert their 
effects, through either gut epithelial integrity o mucosal immunity. Indeed, 
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the distal colon is where fiber is fermented by commensal bacteria to 
produce large quantities of acetate, proprionate and butyrate (40, 20 and 
20 mM, respectively)  (Tan, McKenzie, Potamitis, & al., 2014). Several papers 
have shown that metabolites distribute systemically. Indeed, the exacerbated 
inflammatory reactions observed in germ-free mouse models of disease  
(Herbst, Sichelstiel, Schar, & al., 2011)  (Maslowski, Viera, Ng, & al., 2009) 
are likely related in part to the absence of SCFAs in the gut, blood or tissues. 
In one recent study, the SCFA propionate was shown to affect DCs and 
macrophage biology in the bone marrow and affect Th 2 cell responses in 
the airways  (Trompette, Gollwitzer, Yadava, & al, 2014). Then, SCFAs can 
have a profound effect on systemic macrophage and DCs biology illustrates 
the strong connection between dietary fiber intake and many different types 
of immune responses under the control of DCs or macrophages. 
 
Various G protein-coupled receptors (Gpr) such as Gpr41 (FFAR3 gene), 
Gpr43 (FFAR2 gene), and Gpr109a (HCAR2/NCR1 gene) mediate SCFA 
activities, but the molecular and cellular events responsible for SCFAs-
mediated beneficial effects in the intestine and in other districts are still 
unclear.  
Althoughall those three receptors have been described and even others have 
not been studied yet, Gpr41 and Gpr43 are the most well-mentioned SCFA 
receptors  (Brown, Goldworthy, Barnes, & al., 2003)  (Le Poul, Loison, Struyf, 
& al., 2003) (Hirasawa, Hara, Katsuma, & al., 2008) (Feingold, Moser, 
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Shigenaga, & al.) (Maslowski, Viera, Ng, & al., 2009) (Samuel, Shaito, 
Motoike, & al, 2008).  
Gpr41 is expressed in a variety of tissues and cell types including the colon, 
kidneys, sympathetic nervous system and blood vessels assessing how broad 
is the potential effect of bacterial-metabolites produced in the gut  (Kimura, 
Inoue, Maeda, & al., 2011) (Tazoe, Otomo, Karaki, & al, 2009)  (Xiong, 
Miyamoto, Shibata, & al, 2004). 
Gpr43 is mainly expressed in vasculature and immune cells including 
lymphocytes, neutrophils, monocytes and peripheral blood mononuclear cells 
(PBMC)  (Kimura, Inoue, Maeda, & al., 2011)  (Tazoe, Otomo, Karaki, & al, 
2009)  (Xiong, Miyamoto, Shibata, & al, 2004). Gpr43 has been shown to 
regulate inflammatory responses of the host in response to SCFAs (Le Poul, 
Loison, Struyf, & al., 2003)  (Maslowski, Viera, Ng, & al., 2009). 
Gpr109a was initialli identified as a receptor for niacin  (Wise, Foord, Fraser, 
& al, 2003), and subsequently was also found to respond to beta-D-
hydroxybutyrate as well as butyrate  (Taggart, Kero, Gan, & al, 2005) and its 
activation can apparently suppress carcinogenesis  (Elangovan, Pathania, 
Ramachandran, & al., 2014)  (Singh, Gurav, Sivaprakasam, & al, 2014). 
A recent paper provides key evidence that bacterial-derived butyrate and 
dietary fibers attenuate intestinal inflammation through Gpr109a-mediated 
Treg cell differentiation. This study shows how diet, microbiota, and immune 
cells create a complex communication network essetial for the mainteinance 
of intestinal homeostasis. They observed that FoxP3 Treg cell number and 
frequency in the lamina propria of Gpr109a-/- mice were significantly lower 
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than in WT mice, matching an impaired immunosuppressive IL-10 secretion 
and enhanced production of pro-inflammatory IL-17 (Singh, Gurav, 
Sivaprakasam, & al, 2014). This inflammatory profile may be consequence of 
defective tolerogenic instruction provided by mononuclear cells, so they 
reported a failure in IL-10 release, class 1A aldehyde dehydrogenase 
(Aldh1a) production, and Treg cell generation by butyrate-treated splenic 
DCs and macrophages from Gpr109a-/- mice. Moreover, niacin, which is also 
a Gpr109a ligand and bacterial-derived product, reproduces butyrate effect 
on DCs, macrophages, and Treg cell activities. This highlight the central role 
of Gpr109a in capturing, processing signaling generated by microbial-derived 
metabolites and its essential role in mucosal immunoregulatory fucntions 
afforded by microbial metabolite butyrate. Comparing inflammation between 
GPR43-deficient and Gpr109a-/-mice would help understand the potentially 
divergent role of these receptors in mediating intestinal homeostasis. 
Furthermore, the cell type (epithelial cells, immune cells) responding to SCFA 
exposure may also dictate the extent of the protective response. This is 
clearly demonstrated in immune-cell-derived GPR43 signaling, which 
mediates an anti-inflammatory response  (Maslowski, Viera, Ng, & al., 2009). 
Noteworthy, a recent report showed that butyrate-mediated expansion of 
Treg cells is Gpr109a independent, suggesting a complex impact of this SCFA 
on immune cell behaviors  (Arpaia, Campbell, Fan, & al., 2013). A deep 
genetic dissetion of all the cell compartment for all the receptors involved 
would be necessary to fully capture the essence of the cellular network 
responding to microbial metabolites in mice and humans. 
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1.3. GM and the immune system  
 
The intestinal epithelium at the interface between lymphoid tissue and 
microbiota plays a crucial role in the mucosa immune response. The 
fashinating IS's ability to co-evolve with the microbiota during the perinatal 
life allows the host and the microbiota to coexit in a dangerous relationship 
gaining mutual benefit which consists in orchestate, in a highly coordinated 
way, specific immune responses toward millions of foreign antigens and in 
discriminating false alarms triggered by benign antigens  (Brestoff & Artis, 
2013).  
Recent studies have identified a critical role for commensal bacteria and their 
products in regulating the development, homeostasis and function of innate 
and adaptive immune cells  (Chang, Offermanns, & al., 2014)  (Smith, 
Howitt, Panikov, & al, 2013)  (Trompette, Gollwitzer, Yadava, & al, 2014)  
(Atarashi, Tanoue, Oshima, & al, 2013).  
Several recent reviews have described how commensal bacteria are 
recognized by the innate and how individual species or consortia of 
commensal bacterial species can influence distint subsets of the innate and 
adaptive immune rsponse. 
However, an emerging area that has received little attention is how 
metabolites and nutrients derived from commensal bacteria regulate the host 
immune system. Commensal bacteria are key regulators of digestion, 
extraction, synthesis and absorption of many nutrients and metabolites 
including bile acids, lipids, amino acids, vitamins and short-chain fatty acids. 
 22 
These metabolites derived from commensal bacteria are directly linked to 
diet and digestion and are considered to be diet-dependent microbial 
products  (Tremaroli & Bachked, 2012).  
Nutrients and metabolites derived from commensal bacteria may regulate 
immune cells via indirect and direct mechanisms. Commensal bacteria-
mediated alterations in the availability or use of energy substrates may 
indirectly influence the development and function of immune cells  (Backhed, 
Ding, Wang, & al., 2004)  (Musso, Gambino, & Cassader, 2011).  
 
The study of germ-free mice led to the discovery that the gut microbiota is 
required for the normal generation and/or maturation of GALTs. GALTs are 
immune structures in which antigen can be taken up and presented by 
antigen-presenting cells, and therefore these structures have important roles 
in lymphocyte functions that lead to inflammation or tolerance. GALTs 
include the Peyer's patches, crypt patches and isolated lymphoid follicles 
(ILFs)  (Bouskra, Brezillon, Berard, & al., 2008). In the fetus, lymphoid tissue 
inducer (LTi) cells promote the development of Peyer‟s patches in the 
absence of resident bacteria, although Peyer‟s patches in germ-free mice are 
smaller in size than those in specific-pathogen-free mice  (Moreau & Corthier, 
1988). 
Unlike Peyer‟s patches, the maturation of ILFs and crypt patches requires 
stimulation by the gut microbiota (Hamada, Hiroi, Nishiyama, & al., 2002)  
(Pabst, Herbrand, Friedrichsen, & al, 2006). Specifically, incomplete 
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maturation of ileal and colonic ILFs is observed in mice that are deficient in 
various pattern recognition receptors (PRRs). 
Recently it has been recognized that the gut microbiota can influence 
immune functions beyond the gut in mice and humans. Specific bacterial 
species have previously been associated with the presence of certain T-cell 
subsets within the intestines. For instance, colonization of mice with a single 
commensal microbe, segmented filamentous bacteria (SFB), is sufficient for 
induction of the Th17 subset of CD4+ T cells  (Ivanov, Atarashi, Manel, & al., 
2009). These cells produce the cytokines IL-22 and IL-17, promoting the 
production of antimicrobial peptides and tissue repair, and enhance 
resistance to Citrobacter infections (Ivanov, Atarashi, Manel, & al., 2009)  
(Korn, Bettelli, Oukka, & al., 2009). Generation of Th17 cells can also be 
promoted via sensing of bacteria-derived ATP by dendritic cells (DCs), 
promoting the expression of Th17-inducing cytokines IL-6 and IL-23  
(Atarashi, Nishimura, Shima, & al., 2008). Colonization of mice with Clostridia 
species from clusters IV, XIV, and XVIII isolated from human feces enhances 
Treg cell abundance and also increases the production of potent anti-
inflammatory molecules such as the cytokine IL-10 (Atarashi, Tanoue, 
Oshima, & al, 2013) (Atarashi, Tanoue, Shima, & al., 2011). Further, 
addiction of cecal extracts from these mice to human and mouse IEC cell 
lines led to their production of TGF-1, a major cytokine involved in Treg 
differentiation in the intestine. It also has been observed that cecal extracts 
contained high concentration of SCFAs and addition of a combination of 
purified acetate, propionate and butyrate to IECs also induced TGF-1 in 
 24 
vitro. All these evidences suggest that the production of SCFAs is likely 
responsible for the increase in the Treg cell numbers and they represent the 
link that previously was unkown by the scientific community. 
Later on several papers have been published about the receptors and 
sensors that let possible the uptake of SCFAs from the environment and in 
how many districts far from the gut are sensitive to them.  
Mice deficient in a single G protein–coupled receptor, Gpr3, have a 
profoundly altered inflammatory response. Gpr43-deficient mice (Ffar2–/–; 
called „Gpr43–/–‟ here) have exacerbated and poorly resolving inflammation 
in the KxB/N serum-induced arthritis model and a model of allergic airway 
inflammation induced by ovalbumin plus aluminum hydroxide, as well as in 
colitis models, and Gpr43–/– neutrophils have an intrinsic hyper-reactive 
phenotype  (Maslowski, Viera, Ng, & al., 2009). Gpr43 is expressed mainly on 
cells of the innate immune response and inflammatory cells, such as 
neutrophils, eosinophils and activated macrophages. SCFA can also bind 
other GPCRs, including Gpr41 (but with different affinity and SCFA 
preference) (Le Poul, Loison, Struyf, & al., 2003), and SCFA, particularly 
butyrate, inhibit histone deacetylases and inhibit activation of the 
transcription factor NF-κB. Germ-free mice devoid of microbiota have very 
low concentrations of SCFAs and also show exacerbated or poorly resolving 
responses in many models  (Maslowski, Viera, Ng, & al., 2009), similar to the 
response of Gpr43–/–. Several are the pathways by which the microbiota 
regulates inflammatory responses in the gut and more broadly. 
Bacteroidetes, for istance, use fiber for glycan synthesis and Bacteroides 
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fragilis one of our commensal bacteria belonged to this phylum, produce a 
particular glycan, polysaccharide A, which has strong anti-inflammatory 
effects protecting mice from inflammatory bowel disease through the local 
increase production of IL-10 by inducing T reg cells  (Round & Mazmanian, 
2010). An another example is represented by the peptidoglycan (PTGN), 
bacterial product that can modulate peripheral immune function spreading to 
the blood and priming the innate immune system to kill certain bacterial 
pathogens  (Clarke, Davis, Lysenko, & al., 2010). 
Although the gut microbiota may be one mechanism for the regulation of 
immune responses, it is also likely that dietary substances also directly affect 
immunity. The ω-3 fatty acids exert anti-inflammatory effects through 
binding to Gpr120 (Oh Da, Talukdar, Bae, & al., 2010). Gpr120 is expressed 
mostly by macrophages, and the binding of ω-3 fatty acids to this GPCR 
represses the production of tumor necrosis factor and interleukin-6 and 
macrophage induced tissue inflammation. Thus, the binding of fatty acids to 
Gpr120 and Gpr43 represent a new mechanism for the immune system 
regulation, and -up to date- these GPCRs are the two leading molecules that 
could be the mediators of the effects of diet on inflammatory response. 
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1.4. Immune system: a general overview 
 
The immune system consists of innate and adoptive parts: the innate IS that 
is the sum of physical and chemical blocks, through reactivity of local 
nonspecific and specific cells recruited to the site of inflammation and the 
adaptive IS that acts as a specific second line, responding to antigen 
variability and producing immunological memory  (Abbas, Litchman, & Pillai, 
2012).  
It is conceptually established that it can be divided in two basic components: 
the innate immune system and the adaptive immune system. The primary 
aim of the innate immune cells is to provide a rapid non-specific response to 
any pathogens or foreign aggressors possessing foreign antigens (Janeway & 
Medzhitov, 2002) (Steinman & Idoyaga, 2010). On the other hand, the 
primary aim of the adoptive immune cells is to provide a latent but higly 
specific response against those "non-self" antigens and to generate an 
"immune memory" against those ones to counter similar insults in the future 
more quickly  (Vesely, Kershaw, RD, & al, 2011)  (Matzinger, 2002). 
Together these two parts of the immune system collaborate to initiate acute 
inflammation ultimately culminating in its resolution and healing after they 
have taken care of the "non-self" aggressors or insult.  
Most notable innate immune cells include macrophages, natural killer (NK) 
cells, dendritic cells (DCs), various myeloid lineage subsets, neutrophils, 
basophils, and eosinophils  (Janeway & Medzhitov, 2002)  (Green, Ferguson, 
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Zitvogel, & al., 2009); while the most notable  adaptive immune cells include 
T and B lymphocytes  (Vesely, Kershaw, RD, & al, 2011). 
The initial reaction orchestrated by innate immune cells consists of capturing, 
clearing up or destroying the source of injury, infections, or diseased cells, 
followed by priming of the adaptive immune cells against antigens derived 
from the "non-self"  (Janeway & Medzhitov, 2002) (Steinman & Idoyaga, 
2010). This adaptive immune cell priming helps to initiate more specific 
responses against the acquired antigens and leading to their eradication. 
 
 
 
1.4.1. Dendritic cells  
 
Dendritic cells (DCs) are professional antigen-presenting cells within the 
immune system. They are continuously produced from hematopoietic stem 
cells in the bone marrow and are widely distributed, as immature DCs, into 
both lymphoid and non-lymphoid tissues  (Banchereau & Steinman, 1998)  
(Cella, Sallusto, & Lanzavecchia, 1997)  (Reis e Sousa, Sher, & Kaye, 1999)  
(Moser & Murphy, 2001). Immature DCs, including epidermal Langerhan‟s 
cells, splenic marginal zone DCs and interstitial DCs within non-lymphoid 
tissues, continuously sample self-antigen to maintain T cell self-tolerance  
(Banchereau & Steinman, 1998).  
DCs in general possess a diverse repertoire of surface receptors (and 
intracellular receptors) that help them in environmental sensing and to carry 
out rapid innate immunity-related functions (Steinman & Idoyaga, 2010)  
 28 
(Mellman, 2013). Such receptors include various scavenging or phagocytic 
receptors like CD91, integrins, CD36, surface pattern recognition receptors 
(PRRs) like toll-like receptors (TLRs), and intracellular PRRs like NOD-like 
receptors (NLRs)  (Lutz & Schuler, 2002)  (Simmons, Wearsch, Canaday, & 
al, 2012) (Reis e Sousa C. , 2004). 
DC-based PRRs help in detection and stimulation of danger signals like 
pathogen-associated molecular patterns (PAMPs)  or damage-associated 
molecular pattern (DAMPS)  (Matzinger, 2002). 
Dendritic cells are also special in terms of their antigen processing 
machinery. Classically (for non-professional APCs and normal cells), antigens 
derived from intracellular sources are presented by the major 
histocompatibility complex (MHC) class I presentation system while 
extracellular antigens are preferentially processed for MHC class II 
presentation (Romao, Gannage, & Munz, 2013). This unique ability to cross-
present antigen to adaptive immune cells is also behind DC's role as APCs. 
 
DCs can exist in two main states, steady state immature dendritic cells (im-
DCs) and fully mature DCs (m-DCs) (Mellman, 2013) (Reis e Sousa C., 2006). 
The distinction between immature and mature DCs is partly based on 
changes occurring on two crucial levels: phenotypic and functional. 
Phenotypic maturation is attained when DCs up-regulate surface maturation 
ligands such as CD80, CD83, and CD86 along with MHC class II. DCs 
stimulated on the functional level exhibit the ability to secrete cytokines 
where the balance between inflammatory or immunostimulatory cytokines 
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(e.g., IL-12, IL-6, IL-1) and immunosuppressive cytokines (e-.g., IL-10, 
TGF-) is decided by the "environmental context"  (Steinman & Idoyaga, 
2010)  (Reis e Sousa C., 2006)  (Reis e Sousa C. , 2004). 
Im-DCs are poor stimulators of T cell proliferation, as they lack the requisite 
MHC molecules and costimulatory receptors, and they are located in most 
tissues where they are capable of capturing antigens. Upon encountering a 
powerful immunological stimulus, im-DCs convert into m-DCs, thus switching 
from an antigen-capturing mode into a antigen-presenting and T cell-
stimulating mode  (Vander Lugt, Khan, Hackney, & al, 2014). The m-DCs 
express higher levels of costimulatory molecules, MHC molecules and 
proinflammatory cytokines than im-DCs thus it seems that while m-DCs 
induce a state of immune activation, im-DCs can induce a state of immune 
tolerance (Lechler, Ng, & Steinman, 2001) (Macagno, Napolitani, 
Lanzavecchia, & al., 2007)  (Banchereau & Steinman, 1998)  (Cella, Sallusto, 
& Lanzavecchia, 1997)  (Reis e Sousa, Sher, & Kaye, 1999).  
Cytokines and chemokines produced by m-DCs are important in determing 
the type of immune response, including Th1, Th2 and Th17 responses, 
leading to cellular, humoral and autoimmune responses, respectively  
(Gutcher & Becker, 2007). 
Some studies suggest that DCs have the capacity to induce different types of 
T cell–mediated immune responses, depending on their lineage, maturation 
stage and activation signals. The first experimental evidence suggesting that 
DCs may direct the type of T cell–mediated immune response came from the 
observation that DCs could produce the T helper subset 1 (Th1)-polarizing 
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cytokine interleukin 12 (IL-12)  (Macatonia, Hosken, Litten, & al., 1995)  
(Cella, Scheidegger, Palmer-Lehmann, & al., 1996)  (Kotch, Stanzl, 
Jennewein, & al., 1996)  (Sousa, C, Hieny, Scharton-Kersten, & al, 1997). In 
human blood there are two distinct types of DC precursor: these are myeloid 
monocytes (pre-DC1s) and plasmacytoid DC precursors (pre-DC2s)  (Rissoan, 
Soumelis, Kadowaki, & al., 1999).  
In humans, DCs showed different effector functions, which depended on 
multiple factors, in directing T cell responses. Whereas DC1s at a mature 
stage induce TH1 differentiation and strong cytotoxic T lymphocyte (CTL) 
responses  (Rissoan, Soumelis, Kadowaki, & al., 1999), DC1s at an immature 
stage induce IL-10–producing CD4+ and CD8+ regulatory T cells  (Jonuleit, 
Schmitt, Schuler, & al., 2000)  (Dhodapkar, Steinman, Krasovsky, & al., 
2001)  (Gilliet & Liu, 2002). Pro-inflammatory and antiinflammatory factors 
also affect DC function. Immature DC1s derived from monocytes after 5–7 
days of culture with granulocyte– macrophage colony-stimulating factor (GM-
CSF) and IL-4 induce both Th1 and Th2 differentiation (Kalinski, Hilkens, 
Wierenga, & al., 1999). 
Thus, the unique capacity of DCs to respond to microbial signals and to 
subsequently activate naive T cells enables these cells to determine the 
outcome of antimicrobial immunity and the streght of the immune response. 
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2. Haematopoietic stem cell transplantation 
and immuno reconstitution 
2.1. Haematopoietic stem cell transplantation: 
overview 
Haematopoietic stem cell transplantation (HSCT)  is a widely used treatment 
for replacement of nonfunctioning organs and tissues with healthy organs or 
tissues. Technically, transplantation is the process of taking cells, tissues, or 
organs, called graft, from one individual and placing them into a different 
individual. 
Transplant immunologists have developed a special vocabulary to describe 
the kinds of cells and tissues encountered in the transplant setting. A graft 
transplanted from one individual to the same individual is called an 
autologous graft. A graft transplanted between two genetically identical or 
syngeneic individuals is called a syngeneic graft  (Abbas, Litchman, & Pillai, 
2012). A graft transplanted between two genetically different individuals of 
the same species is called as allogeneic graft (or allograft). 
Initially, the principal source of HSCs was bone marrow (BM) from an HLA 
identical sibling for transplantation in children and young adults. 
Subsequently, the choice of donors and the sources of HSCs have enlarged, 
extending transplant indications to more patients, especially adults. Today, 
transplant physicians must choose among stem cell sources between bone 
marrow, granulocyte colony-stimulating factor (GCSF)-mobilized peripheral 
blood stem cells (PBSC), or umbilical cord blood (UCB). The donor can be an 
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HLA identical sibling, an matched unrelated donor (MUD), a haploidentical 
family peripheral blood stem cell or bone marrow donor or, an HLA-
mismatched unrelated UCB donor  (EBMT, 2012). 
Allogeneic hematopoietic stem cell transplantation (aHSCT) was initially 
developed for two purposes. First, it was a strategy to treat individuals with 
inherited anaemias or immune deficiencies by replacing the abnormal 
hematopoietic system with one from a healthy individual. Second, it allowed 
the delivery of myeloablative doses of radiation and/or chemo therapy to 
patients with cancer. Termed „high-dose‟ therapy, myeloablative conditioning 
generates increased killing of tumor cells compared with conventional doses 
of radiation and chemotherapy. Myeloablative therapy can cure some 
patients who would otherwise relapse, but it results in the permanent loss of 
the patient‟s bone marrow function, requiring rescue with hematopoietic 
stem cells, which are administered as an intravenous infusion (Kolb, 2008). 
 
Transplant carries a significant risk of morbidity and mortality, so the 
decision to proceed with HSCT must carefully balance risks and benefits. 
Allogeneic transplants come with a risk of graft-versus-host disease (GvHD), 
but are also associated with lower rates of malignant relapse owing to an 
immune-mediated graft-versus-tumor (GVT) effect. The most impacting 
complications are infections, relapse, graft-versus-host disease (GVHD), and 
second malignancies which are due in part due to immune deficiency or 
deregulation of the immune system (IS). Studying immune reconstitution has 
it challenges and human studies are complicated as immune reconstitution 
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can be influenced by many factors, for which one cannot always control. 
These can be divided into pre-, peri- and post-transplant factors ( 
Figure 3). Pre-transplant (pre-HSCT) factors include underlying disease, prior 
chemotherapy or radiation, nutritional status, patient and donor age, and 
prior exposure to or infection with microorganisms. Peri-transplant (Peri-
HSCT) factors include conditioning, stem cells source, graft manipulation, 
donor-recipient matching for human leukocyte antigen (HLA) and non-HLA 
antigens and peri-transplant infections. Post-transplant (Post-HSCT) factors 
include pharmacologic GVHD prophylaxis, donor lymphocyte infusions, 
antibiotic treatment and prophylaxis, the development of GVHD (Bosh, Khan, 
& Storek, 2012). 
 
 
Figure 3: Schematic rapresentation of the most important factors that influence the 
trasplantation outcome considering the pre-, peri-, and post-HSCT periods.
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2.2. Graft-versus-host disease  
 
Graft-verus-host disease (GvHD) is a major cause of non-relapse morbidity 
and mortality, affecting up to 40-60% of transplanted patients (Jagasia, 
Arora, & Flowers, 2012) and accounting for 15% of death after aHSCT  
(Pasquini & Wang, 2013). 
GvHD was initially reported by Barnes, Loutit and Micklem and classically 
defined by Billingham as a syndrome in which donor immunocompetent cells 
recognize and attack host tissues in immunocompromised allogeneic 
recipients (Barnes, Loutit, & Micklem, 1962)  (Billingham, 1966–1967). 
Many variables are correlated to the GvHD onset such as stem cell source, 
age of donor and recipient, preparative regimen and prophylaxis can impact 
the likelihood and severity of GvHD. Children risk less for GvHD than adults; 
however, that risk is still significant especially when using alternative donor 
sources. 
Acute GvHD and chronic GvHD involve distinct pathological processes: acute 
GvHD has strong inflammatory components, whereas chronic GvHD displays 
more autoimmune and fibrotic features. Acute GvHD, typically occurring 
between the time of the engraftment through 100 days after transplant and 
can lead devastating consequences on the skin (81% of patients), gut (54%) 
and liver (50%)  (Ferrara, Levine, & Holler, 2009). 
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Chronic GvHD typically occurs after 100 days, although this temporal 
distinction is blurring with strategies such as reduced-intensity conditioning, 
and an overlap syndrome is recognized that shares features of both.  
Billingham formulated three requirements for development of GVHD: (1) the 
graft must contain immunologically competent cells; (2) the recipient must 
express tissue antigens that are not present in the transplant donor; and (3) 
the patient must be incapable of mounting an effective response to eliminate 
the transplanted cells.  
The immunologically competent cells are T cells and hence GVHD can 
develop in various clinical setting when tissues containing T cells (blood 
products, bone marrow, and solid organs) are transferred from one person to 
another who is not able to eliminate those cells. Patients whose immune 
systems are suppressed and who receive white blood cells from another 
individual are at especially high risk for the disease. The pathophysiology of 
the GvHD is a complex but fast process that arises when donor T cells 
respond to genetically defined proteins on host cells, like human leucocyte 
antigens (HLA), which are highly polymorphic and are encoded by the major 
histocompatibility complex (MHC)  (Krensky, Weiss, Crabtree, & al., 1990),  
(Peterson, Frank, Pace, & al, 2008)  (Welniak, Blazar, & Murphy, 2007). 
Despite HLA identity between a patient and donor, about 40% of recipients 
of HLA-identical grafts develop systemic acute GvHD that needs treatment 
with high-dose steroids. Moreover, polymorphisms in both donors and 
recipients of cytokines that have a role in the classic cytokine storm of GVHD 
have been implicated as risk factors for the disorders (Antin & Ferrara, 
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1992). In fact, some studies have showed a correlation between tumor 
necrosis factor alfa (TNF-α), interleukin 10 (IL-10) and interferon gamma 
(IFN-γ) variants with GvHD (Lin, Storer, Martin, & al., 2003)  (Dickinson & 
Charron, 2005). 
 
2.2.1. Pathophysiology of acute GvHD  
 
For what concern the pathophysiology of acute GvHD, the disease is 
indicative of exaggerated but typical inflammatory mechanisms mediated by 
donor lymphocytes infused into the recipient and the recipient‟s tissues that 
stimulate donor lymphocytes have usually been damaged by underlying 
disease, previous infections, and the transplant conditioning regimen. As a 
result, these tissues produce molecules such as proinflammatory cytokines 
and chemokines, which increase expression of key receptors on antigen-
presenting cell (APC), thereby enhancing cross-presentation of polypeptide 
proteins to the donor immune cells that mediate GvHD. 
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Figure 4: The three main phases of GvHD  (by Ferrara, et al., 2009). 
 
Severity of acute GvHD is ascertained by the extent of involvement of the 
three main target organs. According with the Seattle grading system, have 
been listed different grades: I (mild), II (moderate), III (severe), and IV 
(very severe)  (Glucksberg, Storb, Fefer, & al., 1974).  
Skin is most frequently affected and is usually the first organ involved, 
generally coinciding with engraftment of donor cells. The characteristic 
maculopapular rash is pruritic and can spread throughout the body. 
Gastrointestinal-tract involvement of acute GVHD usually presents as 
diarrhea but can also include vomiting, anorexia, abdominal pain, or a 
combination when severe. Liver disease caused by GVHD can be difficult to 
distinguish from other causes of liver dysfunction such as veno-occlusive 
disease, toxic drug effects, viral infection, sepsis, or iron overload; the 
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histological features of hepatic GVHD are endothelialitis, lymphocytic 
infiltration of the portal areas, and bile-duct destruction. 
On the basis of this knowledge, the progression of acute GvHD can be 
summarized in three sequential steps or phases: (1) activation of APCs; (2) 
donor T-cell activation, proliferation, differentiation and migration; and (3) 
target tissue destruction (Figure 4).  
o The first phase involves damage to host tissues by inflammation 
from the preparative chemo- and/or radiotherapy regimen that leads 
to the release of proinflammatory cytokines such as tumor necrosis 
factor-α (TNF-α) and interleukin-1 (IL-1) and danger signals such as 
adenosine-5‟-triphosphate (ATP) as well as extracellular matrix 
proteins such as biglycans that promotes activation and maturation of 
antigen-presenting cells (APCs) (Zeiser, Penack, Holler, & al., 2011). 
This is furthered by damage to the gastrointestinal epithelium, 
allowing translocation of lipopolysaccharide, which can activate innate 
immunity through Toll-like receptors, furthering the cytokine cascade  
(Hill & Ferrara, 2000) (Figure 5). 
o In the second phase, donor T-cell activation is triggered by recipient 
antigens presented by host APC and sustained by donor APC both 
recipient and donor antigen-presenting cells, as well as inflammatory 
cytokines trigger activation of donor-derived T cells, which expand 
and differentiate into effectors cells, that results in the transcription of 
genes for cytokines in a positive feedback. The activation is mediated 
by human leukocyte antigen (HLA) proteins encoded by the major 
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histocompatibility complex (MHC); in addition to the interaction 
between the T-cell receptor and MHC, T-cell activation requires 
signaling between costimulatory molecules such as CD28 (present on 
the T cell) and B7.1 or B7.2 (CD80 or CD86, present on the APC); 
other T-cell:APC costimulatory signaling pairs include inducible 
costimulator (ICOS) (CD278):B7H (CD275), OX40 (CD134):OX40L 
(CD252), CD40L (CD154):CD40, and 4-1BB (CD137):glucocorticoid-
induced tumor necrosis factor receptor (GITR). The absence of these 
costimulatory signals, particularly CD28:B7.1/B7.2, can lead to anergy; 
furthermore, this interaction can be blocked by coinhibitory molecules 
such as CTLA4 (CD152), which competes with CD28 for B7.1/B7.2. 
Programmed death-1 (PD-1) (CD279): programmed death ligand 1 
(B7H1, CD274) are another pair of inhibitory molecules that can 
induce anergy or tolerance. Models that block these costimulatory or 
coinhibitory interactions have been shown to reduce or exacerbate 
GVHD, suggesting possible therapeutic targets  (Kwon, 2010). 
o in the third phase, activated T cells migrate from secondary 
lymphoid organs to target tissues through a combination of 
chemokine-receptor, selectin-ligand, and integrin-ligand interactions  
(Wysocki, Panoskaltsis-Mortari, & al, 2005); selectins and integrins 
mediate rolling and tethering of lymphocytes along high endothelial 
venules through interactions with their matching ligands. For example 
interactions between L-selectin (CD62L) and α4β7 integrin expressed 
on T cells and peripheral node addressin and mucosal addressin cell 
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adhesion molecule expressed on secondary lymphoid tissue mediate 
homing to mesenteric lymph nodes and Peyer‟s patches and induction 
of gut GVHD  (Dutt, Ermann, Tseng, & al., 2005). Once activated 
donor T cells reach target organs mediate cytotoxicity against target 
host cells through Fas-Fas Ligand interaction, perforin-granzyme B, 
production of tumor necrosis factor-α (TNF-α)  (Braun, Lowin, French, 
& al., 1996). Cytokines such as TNF-α, IFN-γ, IL-2, IL-7, IL-10, and 
others also appear to be essential to regulating leukocyte recruitment 
and tissue destruction; these effects are dependent on strength, 
timing, and other interactions, making the effects of individual 
cytokines difficult to predict  (Welniak, Blazar, & Murphy, 2007). 
 
 
 
Figure 5: Pathopysiology of GvHD  and GVT effects (modified by Jenq e Van der Brink, 
2010). 
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2.3. Immune reconstitution after aHSCT  
The restoration of a functional immune system is one of the main factors 
influencing the clinical outcome of aHSCT. The post-HSCT period is 
characterized by multiple immune defects that expose the patient to a high 
risk of opportunistic infections, second malignancies and disease relapse; all 
these complications are due in part to immune deficiency or dysregulation of 
the IS.  
The duration of this period may vary according to several variables, including 
patient‟s age, the immune status before transplant, the intensity of the 
conditioning regimen, the source of stem cells, graft manipulation, the 
degree of donor compatibility, and pharmacological immune suppression. 
Although often used interchangeably, it is therefore important to distinguish 
between immune reconstitution, which refers to qualitative immune cell 
repopulation, and immune recovery, which regards to their qualitative 
restitution  (Shiobara, Harada, Mori, & al., 1982). 
Studying and following immune reconstitution has its challenges. 
Observations in mice (typically inbred and relatively pathogen-free) cannot 
be applied to humans (outbred and harboring multiple pathogens). In fact, 
quantitative recovery of T cells following murine HCT takes weeks to months, 
whereas it takes months to years following human HCT. Furthermore, human 
studies are complicated as immune reconstitution can be influenced by many 
factors, for which one cannot always control. Although the quantitative 
aspects of immune reconstitution post-transplant and the qualitative features 
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of immune recovery have been the subject of several studies, a tight 
association between measurable immune biomarkers and the clinical 
outcome of HSCT, is currently missing. So far, the specific issue of validating 
thresholds of immune measurements that may help predicting the incidence 
of major post-transplant events has been approached by single-center with 
small-size studies. While sometimes sufficiently powered to obtain 
statistically significant results, these studies often failed to draw definitive 
conclusions that may be relevant to daily clinical practice. Conversely, the 
lack of harmonized methods for immune biomarkers measurements and the 
great heterogeneity of the transplant populations between the different 
studies have left more thoughts unresolved than meaningful unique results.  
The normalization of granulocytes, monocytes and NK cell numbers usually 
occurs the first week and (with the possible exception of NK-cells) coincides 
with their full competence. In the other hand, the normalization of T and B 
cell numbers may take much longer and does not necessarily associate with 
their immediate functional restitution  (Shiobara, Harada, Mori, & al., 1982). 
The quantitative reconstitution of T cells post-transplant occurs through two 
main mechanisms: (1) the early peripheral expansion of donor-derived 
memory T cells present in the graft, that takes weeks (2) the late increase 
of host-tolerance naïve T cells originating from donor stem cells after thymic 
education, which, depending on donor age, occurs in months  (Van der 
Brink, Alpdogan, & Boyd, 2004). 
Studies on immune recovery after HCT have been performed extensively in 
adults  (Lum, 1987)  (Verma & Mazumder, 1993)  (Storek, Witherspoon, & 
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Storb, 1995). It is well known that GvHD, its prophylaxis or treatment, and 
CMV infections influence the recovery of the immune system after allogeneic 
HCT in adults  (Noel, WItherspoon, Storb, & al., 1978)  (Meyers, Flournoy, & 
Thomas, 1980)  (Parkman & Weinberg, 1999). Persistent CD4+ T-cell 
depletion post allogeneic HCT seems to be related primarily to age-
associated thymic insufficiency (Mackall, Fleisher, Brown, & al, 1995)  
(Storek, Witherspoon, & Storb, 1995). 
In children, however, only limited data on immune reconstitution post HCT 
with special regard to factors affecting the speed of recovery are available  
(Foot, Potter, Donaldson, & al., 1993)  (Kook, Goldman, al., & al., 1996)  (De 
Vries, Van Tol, Van der Bergh, & al., 2000). The role of age in CD4+ T-cell 
recovery was raised by a paediatric study, which showed no difference 
between T-cell recovery after allogeneic bone marrow transplantation (BMT) 
in children and in adults  (De Vries, Van Tol, Van der Bergh, & al., 2000). 
Data on immune reconstitution after autologous HCT in children is extremely 
modest (Bengtsson, Smedmyr, Festin, & al., 1989)  (Takaue, 1991)  (Small, 
Papadopoulos, Boulad, & al, 1999)  (Kamani, Kattamis, Carroll, & al., 2000). 
The majority of studies were based on very low numbers of patients: the 
largest group of 41 children was analyzed by Takaue (1991) (Takaue, 1991). 
Furthermore, there was no large, single-center comparison of immune 
recovery between pediatric recipients of autologous and allogeneic grafts. 
Studies in adults show faster T-cell recovery after autologous HCT  
(Shiobara, Harada, Mori, & al., 1982), but some recent data suggest 
prolonged CD4+ T-cell depletion both in adults and in children post 
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autologous HCT  (Nordoy, Kolstad, Endresen, & al., 1999) (Laurenti, Sica, 
Sorà, & al., 2000)  (Mackall, Stein, Fleisher, & al., 2000). Another interesting 
study has been published comparing allo- and auto-transplanted children 
with regard to factors affecting the speed of recovery  (Kalwak, Gorczynska, 
Toporski, & al., 2002) and some other informations about factors affecting 
lymphocyte subset reconstitution after cord blood transplantation children 
have been included in the literature  (Niehues, Rocha, Filipovich, & al., 
2001). More recently a study of 32 pediatric patients provided preliminary 
evidence that patients with slow recovery of cytotoxic T cells have a high risk 
of relapse or life-threatening infections  (Koel, Bochennek, Zimmermann, & 
al., 2007). In 2010 has also has been published a innovative approach using 
a multivariate analysis methods in order to classify into high-risk and low-risk 
groups of children patients based on the speed of cellular immune 
reconstitution, offering new prospectives  (Koening, Huenecke, Salzmann-
Manrique, & al., 2010). 
The progress of immune reconstitution is different in each patients and it 
creates several issues for biologists and clinicians to find reliable markers 
useful to predict risk of infections, relapse during the reconstitution period 
after HSCT. 
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2.4. GM and aHSCT 
The impact of the microbiota on GVHD is known to be significant. Studies in 
mice have shown reduction of GVHD with gut-decontaminating antibiotics  
(Van Bekkum, Roodenburg, Heidt, & al., 1974) and transplantation in germ-
free conditions  (Jones, Wilson, & Bealmear, 1971). This led to efforts to 
eliminate bacterial colonization in allogenic bone marrow transplantation 
(BMT) patients, combining gut decontamination with a near-sterile 
environment (Storb, Prentice, Buckner, & al., 1983). Initial reports were 
promising, but subsequent studies could not confirm a benefit (Passweg, 
Rowlings, Atkinson, & al., 1998)  (Russel, Chaundhry, Booth, & al., 2000). 
Other approaches include targeting anaerobic bacteria (Beelen, Elmaagacli, 
Muller, & al., 1999) and introducing potentially beneficial bacteria (Gerbitz, 
Schultz, Wilke, & al., 2004), with some reduction of GVHD. These initial 
studies, however, have been few in number, and no consensus exists 
between BMT centers regarding how to target the flora. Until recently, a 
reliance on microbiological culture techniques to characterize flora 
composition limited these studies. Culture-independent techniques such as 
ribosomal RNA (rRNA) gene sequencing have demonstrated that a large 
majority of the estimated 500–1,000 bacterial species present in the human 
intestinal tract are not detected by culture techniques  (Manson, Rauch, & 
Gilmore, 2008). In one of the last study carried out by Jenq RR. et al. has 
been readdressed the relationship between GVHD and the microbiota in 
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murine and human allogenic BMT recipients. 
The microbiota, in turn, can modulate the severity of intestinal inflammation. 
In mouse models of GVHD, has been observed loss of overall diversity and 
expansion of Lactobacillales and loss of Clostridiales. Eliminating 
Lactobacillales from the flora of mice before BMT aggravated GVHD, whereas 
reintroducing the predominant species of Lactobacillus mediated significant 
protection against GVHD. In parallel they then characterized gut flora of 
patients during onset of intestinal inflammation caused by GVHD and found 
patterns mirroring those in mice. Has been identified an increased microbial 
chaos early after allogeneic BMT as a potential risk factor for subsequent 
GVHD (Jenq, Ubeda, & Taur, 2012).  
After two years the same research group have shown that the abundance of 
bacteria belonging to the genus Blautia, a commensal commonly found in the 
intestinal tract of humans, predicts for protection from life-threatening GvHD 
in allo BMT patients; furthermore, in murine models, introducing a species of 
Blautia of murine origin reduces GvHD severity. Interestingly, it appears to 
do so by inducing regulatory T cells with generation of short-chain fatty acid 
metabolic byproducts  (Jenq & van der Brink, 2014). Recently it also has 
been shown that mortality outocomes following aHSCT were significantly 
worse in patients with lower intestinal diversity; in fact, overall survival at 3 
years was 36%, 60%, and 67% for low, intermediate, and high diveristy 
group, respectively  (Taur, Jenq, Perales, & al., 2015). 
Taken together, these data support the hypothesis that the GM composition 
and diversity exert an important role also in transplanted patients and 
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suggest that a new research field on flora manipulation might open new 
clinical trials in order to reduce intestinal inflammation and improve 
outcomes for allogeneic BMT recipients.  
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3. PROJECT OUTLINE 
 
The GM structure, as an active component of the human immune system -
and the resulting pattern of immunological interaction with the host – can be 
of primary importance in governing the fate of the immunological 
reconstitution in patients who undergoing aHSCT, predisposing or protecting 
from the aGvHD onset and other complications. 
The study carried out along three year of PhD course was primarily divided in 
three parts:  
I. the phylogenetic and functionality study of the gut microbiota in 
pediatric patients undergoing allogeneic hematopoietic stem cell 
transplantation; 
II. the transcriptome analysis of human DCs exposed to SCFAs in order to 
explore potential immunomodulatory effect of GM metabolites on one 
of the immune system's cell type that play the main role on the  
aGvHD onset; 
III. the descriptive study of the early immune system's peripheral subsets 
reconstitution in terms of quantitative immune cells repopulation, and 
the analysis of a possible correlation between GM and IS during this 
delicate period of body recovery. 
 
A common aim that has held all the three main goals pursued to investigate 
"GM predictor configurations" predisposing to or protective from aGvHD and 
to understand whether the composition of gut microbiota could exert an 
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immunomodulatory effect during the immune system's reconstitution after 
aHSCT.  
Considering the state of art that strongly supports the idea that the GM 
exerts an important shaping role to the immune system, it has been 
considered that changes in dietary habits may modulate the composition of 
the gut microbiota leading to an increase of bacterial metabolites that could 
exert a protective role against the onset of aGvHD or to reduce the rate of 
this inflammatory response. The aim of this part was also to characterize in 
vitro the effect of SCFAs (acetate, butyrate, and propionate) on the 
immature and mature human monocyte-derived DCs, exploring the 
transcriptional response of one of the most important key regulators of the 
immune system upon exposure to these bacterial metabolites. 
In parallel, the immune system reconstitution was monitored by phenotyping 
the lymphocytes populations circulating in blood in order to figure out their 
different trends of recovery and a potential correlation with several variables 
such as infections, aGvHD onset, and the final outcome. The aim of this part 
was to look over and find some reliable markers that might be useful for the 
clinicians to refine ad hoc the pharmacological approach improving also the 
children's lifestyle.  
In fact, most of the available knowledge about the immuno recovery after 
aHSCT in pediatrics has been focused on the late period (after 100 days 
since the transplantation procedure) and very few studies have been 
published regarding the early period considering several challenges in 
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collecting samples for the delicate children status and a hard-to-get parental 
consent.  
All this work has allowed to obtain several interesting results opening new 
perspectives for clinitians and researchers in this field; some of those have 
already been published in Bone Marrow Transplantation  (Biagi, Zama, 
Nastasi, & al., 2015) and some others have been already elaborated and will 
be submitted to a peer-reviewed journal as Nastasi C., Candela M., Gaisler 
C., et al. "Short-chain fatty acids (SCFAs) effect on human monocyte-derived 
dendritic cells (DCs)".  
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4. Materials and Methods 
4.1. I part: GM and SCFAs 
Patients features 
 
The study has been approved by the Ethical Committee of the Sant‟Orsola-
Malpighi Hospital-University of Bologna (ref. number. 19/2013/U/Tess). Ten 
pediatric patients (8 males), who have been chosen among the 23 children 
patients, with age ranging from 2 to 16 years (mean age 8.4 years), who 
underwent HSCT for hematological disorders (2 subjects, Blackfan-Diamond 
anemia (BDA); 2 subjects acute myeloid leukemia (ALM), 6 subjects acute 
lymphoid leukemia (ALL)), were enrolled at the Pediatric Bone Marrow 
Transplantation Unit of the Sant‟Orsola-Malpighi Hospital, Bologna, Italy. 
Exclusion criteria were lack of informed consent, incomplete sample 
collection, and samples not evaluable for technical reasons. Demographic 
and transplant characteristics of the patients are summarized in ( 
Table 1). All children were in a HEPA filtered single room and received 
standard prophylaxis measures to prevent any complications due to 
infections. These include the use of non-absorbable antibiotics (levofloxacin) 
for gut decontamination since the start of conditioning regimen to the 
recovery of the enteral nutrition and neutrophil engrafment  (Bucaneve, 
Micozzi, & Menichetti, 2005). No patient of the cohort had sepsis during the 
time of collection of the samples, so aGvHD and non-aGvHD patients had the 
same exposures to antibiotics. Acyclovir and fluconazole were administered 
for the antiviral and antifungal prophylaxis from day -1 and +2, respectively 
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(Saral, Burns, Laskin, & al, 1981). Neutrophil and platelet engraftment were 
defined as occurring on the first of the three consecutive days on which the 
neutrophil level was 0.5•109/l or higher and the blood platelets were above 
20•109/l, respectively. All patients observed fasting since the day of the 
transplant and stopped it the day of the engraftment, had the clinical 
condition allowed. Only when per os intake was at least 50% of the caloric 
needs, parenteral nutrition was suspended. Foods were introduced gradually 
during the following 3-6 months after HSCT. Of the 10 patients, 5 developed 
aGvHD, 4 of which had skin aGvHD (Grade I-III) according with the Seattle 
grading system (Glucksberg, Storb, Fefer, & al., 1974). The patient who 
developed grade III skin aGvHD was treated with steroids and extracorporeal 
photoaferesis, the other 3 patients with grade I-II skin GvHD received only 
steroids. One (subject 15) developed severe grade IV intestinal aGvHD and 
received steroids, infliximab and extracorporeal phoaferesis.  
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Subject 
Sex / 
Age 
Diagnosi
s 
Donor 
Type 
Stem 
cell 
source 
Conditioning 
regimen 
GvHD 
Prophylaxis 
TNC/Kg 
Engraftment 
(day) 
Acute GvHD 
OUTCOME 
PMN PLT Grade Localization Day Therapy 
4 F/12 AML MUD BM 
BU+EDX 
L-PAM 
ATG-CSA-MTX 4.2x108 +13 +20 I Skin +25 Steroid 
ANED  
2 ys 
5 M/10 ALL MFD BM BU+TT+EDX CSA 2.9x108 +12 +17 III Skin +23 
Steroid - 
PHEC 
ANED 
 2 ys +1/12   
6 M/2 BDA MMUD BM 
BU+TT 
FLUDARA 
ATG-CSA-MTX 10x108 +15 +16 II Skin +15 Steroid 
ANED 
2 ys +2/12  
11 M/9 ALL MUD BM BU+TT +EDX ATG-CSA-MTX 3.4x108 +15 +27 II Skin +11 Steroid 
Dead 
for relapse 
15 M/8 ALL MFD BM BU+ TT+EDX CSA 5.8x108 +12 +17 IV 
Skin 
Gastrointestinal 
tract 
+11 
Steroid - 
PHEC 
Infliximab 
ANED 
1ys +6/12 
16 M/16 ALL MFD BM BU+TT+EDX CSA 4.6x108 +11 +30     
ANED 
1ys +6/12 
19 F/10 ALL MUD BM BU+TT +EDX ATG-CSA-MTX 7.1x108 +34 +35     
ANED 
1 ys +3/12 
20 M/7 ALL MUD BM BU+TT +EDX ATG-CSA-MTX 4.8x108 +12 +15     
ANED 
1 ys+4/12 
22 M/2 BDA MUD BM 
BU+TT 
+FLUDARA 
ATG-CSA-MTX 9.9x108 +13 +14     
ANED 
1ys +3/12 
26 M/8 AML MUD BM BU+EDX+L-PAM ATG-CSA-MTX  7.2x108 +12 +21     
ANED 
1 ys +9/12 
 
Table 1: Anagraphical and clinical information of the enrolled patients.  
Footnotes: F: female, M: Male, AML: acute myeloid leukemia, ALL: acute lymphoblastic leukemia, BDA: Blackfan Diamond anemia, MUD: match unrelated 
donor, MMUD: mismatch unrelated donor, MFD: match family donor, BM: bone marrow, Bu: busulfan, EDX: cyclophosphamide, TT: cyclophosphamide, L-
PAM: melphalan, Fludara: fludarabine, ATG: anti-thymocyte globulin, CSA: cyclosporine, MTX: methotrexate, GvHD: Graft verus Host Disease, TNC: total 
nucleated cells, PMN: polymorphonuclear leukocytes, PLT: platelets, ANED: alive no vidence of disease, ys: years, PHEC: extracorporeal phoaferes. 
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DNA extraction from fecal samples. Total bacterial DNA from fecal 
samples was extracted using DNeasy Blood&Tissue Mini Kit (Qiagen, 
Duesseldorf, Germany) with a modified protocol (Biagi, Nylund, Candela, & 
al., 2010). 250 mg of feces were suspended in 1.2 ml of lysis buffer (500 mM 
NaCl, 50 mM Tris-HCl pH 8, 50 mM EDTA, 4 % SDS). Four 3 mm glass beads 
and 0.5 g of 0.1 mm zirconia beads (BioSpec Products, Bartlesville, OK) were 
added, and samples were treated thrice in FastPrep (MP Biomedicals, Irvine, 
CA) at 5.5 ms for 1 min with 5 min intervals in ice. Samples were heated at 
95°C for 15 min to inactivate pathogens, and centrifuged for 5 min at full 
speed. Supernatants were added of 260 μl of 10 M ammonium acetate and 
kept in ice for 5 min, then centrifuged at full speed for 10 min. Supernatants 
were collected, 1 volume of isopropanol was added and incubated in ice for 
30 min. DNA was precipitated by centrifugation for 15 min at full speed and 
washed with ethanol 70%. Pellets were resuspended in 100 μl of TE buffer 
and treated with 2 μl of DNase-free RNase (10 mg/ml) at 37°C for 15 min. 
Protein removal by Proteinase K treatment and DNA purification with Qiagen 
columns were performed following the manufacturer‟s instructions for Gram 
positive bacteria. Final DNA concentration was determined by using 
NanoDrop ND-1000 (NanoDrop® Technologies, Wilmington, DE). 
16S rRNA gene amplification and pyrosequencing. The V4 region of 
the 16S rRNA gene was amplified by using the primers 520F (5‟-
AYTGGGYDTAAAGNG-3‟) and 802R (5‟-TACNVGGGTATCTAATCC-3‟)  
(Centanni, Turroni, Consolandi, & al., 2013). Primers included at their 5‟ end 
one of the two  
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adaptor sequences used in the 454-sequencing library preparation protocol 
(adaptor A and B), linked to a unique MID tag barcode of 10 bases allowing 
samples identification. PCR mix contained 0.5 µM of each primer, 
approximately 100 ng of template DNA, 2.5 U of GoTaq Flexi Polymerase 
(Promega, Milan, Italy), 200 µM of dNTPs and 2 mM of MgCl2. Thermal 
cycling consisted of initial denaturation at 95°C for 5 min, followed by 35 
cycles of 94°C for 50 s, 40°C for 30 s, and 72°C for 60 s, with a final 
extension step at 72°C for 5 min. PCR amplifications were carried out in a 
Biometra Thermal Cycler T Gradient (Biometra, Göttingen, Germany). 
Amplicons were purified with MinElute PCR Purification Kit (Qiagen), 
quantified using the Quant-iT PicoGreen dsDNA kit (Invitrogen, Leek, 
Netherlands), pooled in equal amounts (creating five 7-plex and one 10-plex 
pools), and again purified by 454-Roche Double Ampure size selection 
protocol with Agencourt AMPure XP DNA purification beads (Beckman Coulter 
Genomics GmbH, Bernried, Germany) according to the manufacturer‟s 
instructions (454 LifeSciences, Roche, Branford, CT). Pools were fixed to 
microbeads to be clonally amplified by emulsion PCR following the GS-FLX 
protocol Titanium emPCR LIB-A (454 LifeSciences, Roche). Beads were 
enriched in order to keep only those carrying identical PCR products on their 
surface, and loaded onto a picotiter plate for pyrosequencing reactions, 
according to the GS-FLX Titanium sequencing protocol. Each pool was 
sequenced in one eighth of a plate. 
 56 
Bioinformatic analysis of 16S rRNA gene sequencing data. 
Sequencing reads were analyzed using the QIIME pipeline (Schnorr, Candela, 
& al., 2014). Briefly, V4 sequences were filtered according to the following 
criteria: (i) read length 150 - 350 bp; (ii) no ambiguous bases (Ns); (iii) a 
minimum average quality score over a 50-bp rolling window of 25. For 
bacterial taxonomy assignment RDP-classifier (version 2.2) was used with 
50% confidence threshold. Trimmed reads were clustered into OTUs at 97% 
identity level and further filtered for chimeric sequences using ChimeraSlayer 
(http://microbiomeutil.sourceforge.net/#A_CS). Alpha-diversity and 
rarefaction plots were computed using four different metrics: Shannon, PD 
whole tree, chao1 and observed species. Weighted and unweighted UniFrac 
distances and Euclidean distance of genus level relative abundance were 
used to perform Principal Coordinates Analysis (PCoA). The R packages Stats 
and Vegan were used to perform statistical analysis. In particular, data 
separation in the PCoA was tested using a permutation test with pseudo F-
ratios (function Adonis in the Vegan package).  
GC-MS determination of SCFAs in fecal samples Aliquots of dried fecal 
samples (about 250 mg) were briefly homogenized after the addition of 1 mL 
of 10% perchloric acid in water and centrifuged at 15,000 x g for 5 min at 
4°C. 500µL of supernatant were diluted 1:10 in water, 10 µL of D8-butyrric 
acid (internal standard, IS) were added to the sample at the final 
concentration of 20 µg/mL (9). The calibration curves were prepared adding 
the internal standard to scalar amounts of the acids in diluted samples or 
water (for external standardization). All the standards (purity > 99%), acetic, 
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propionic, butyric, valeric acids and IS were provided by Sigma-Aldrich 
(Milan, Italy) and were used to prepare calibration solutions for quantitation 
(linear response) and identification. HS-SPME was performed by using a 75 
µm CarboxenTM/polydimethylsiloxane fiber (Supelco, Bellefonte, PA, USA). 
The optimized final extraction conditions were: temperature 70°C, 10 min of 
equilibration time, 30 min of extraction time. The analytes were desorbed 
into the GC injector port at 250°C for 10 min, including fiber cleaning. GC-MS 
analysis was carried out on a TRACE GC 2000 Series (ThermoQuest CE 
Instruments, Austin TX, USA) gas chromatograph, interfaced with GCQ Plus 
(ThermoQuest) mass detector with ion trap analyzer, operating in EI mode 
(70 eV). The capillary GC column was a Phenomenex ZB-WAX (30 m x 0.25 
mm ID, 0.15 μm film thickness), consisting of 100% Polyethylene Glycol. 
Helium (He) was the carrier gas at a flow rate of 1.0 mL min-1. An oven 
temperature program was adopted: initial 40 ºC (hold time: 5 min), then 
ramped by 10 ºC min-1 to 220 ºC (hold time: 5 min). The temperature of 
transfer line and ionization source was maintained at 250 and 200 ºC, 
respectively. The GC was operated in splitless mode; the injector base 
temperature was set at 250 °C. The mass spectra were recorded in full scan 
mode (34-200 amu) to collect the total ion current chromatograms. 
Quantitation was carried out by using the extracted ion chromatograms by  
selecting fragment ions of the  studied analytes (43 and 60 amu for acetic 
acid, 55 and 73 amu for propionic acid, 60 and 73 amu for butyric and valeric 
acids and 63 and 77 amu for IS).  The SCFAs concentration in fecal samples 
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was expressed in micromoles per gram (µmol/g) of feces. Limit of detection 
ranged from 4 to 68 nmol/g.  
T helper cells, T reg cells phenotyping. Whole peripheral blood (PB) 
samples were obtained by venipuncture and were collected in 
correspondence of the fecal samples, when it has been possible.  Each PB 
sample was received in heparinized tube (BD Vacutainer®) and the 
leucocyte counting was determined by SIEMENS ADVIA 2120 Hematology 
System. Peripheral blood mononuclear cells (PBMCs) were separated by 
Ficoll-density gradient centrifugation (Ficoll-Hypaque, GE Healthcare, 
Piscataway, NJ) and used immediately in assays following the isolation.  In 
order to detect CD4+CD25++CD127-FoxP3+ T regulatory cells (Treg), PBMCs 
were immunostained with conjugated monoclonal antibodies (mAb) for 
human CD4 (FITC, BD, clone RPA-T4), CD25 (PE, BD, clone M-A251), CD127 
(PerCP-Cy5.5, BD, clone HIL-7R-M21) for 20 minutes at room temperature 
(RT) in the dark and then were washed and resuspended in 
fixation/permeabilization solution (BD, Cytofix/Cytoperm kit; BD Biosciences 
PharMingen) and intracellular staining was performed following the 
manufacturer‟s instructions using mAb FoxP3 (APC, eBioscience, clone 
236A/E7) mAb. In order to detect CD3+CD4+INF-+ T cells (Th1), 
CD3+CD4+IL-4+ T cells (Th2), CD3+CD4+IL-17+ T cells (Th17), PBMCs were 
stimulated for 5h with PMA(50ng/ml)/Ionomycin(1μg/ml) in the presence of 
BD GolgiStop™ Protein Transport Inhibitor for the last 2h. It has been used 
the Human Th1/Th2/Th17 Phenotytyping Kit (BD Pharmingen™, 
cat#5607751) and has been followed the main manufacturer's instructions 
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with the addition of CD4 (PeCy7, BD, clone SK3) and CD3 (APC-H7, BD, 
clone HIT3a) mAbs before permeabilization steps. Procedure was performed 
as recommended by protocol's kit and for the multicolor staining the kit‟s 
mAb cocktail (CD4 (PerCP-Cy5.5, clone SK3), IL-17A (PE, clone N49-653), 
IFN-GMA (FITC, clone B27) and IL-4 (APC, clone MP4-25D2)) was used. 
Stained cells were analyzed by flow cytometry on FACSCanto™ II (BD) and 
data were analyzed by FACSDiva software (BD). Prior to the analysis, PMT 
values were adjusted running unstained or unstimulated cells to exclude 
autofluorescence and to control the intensity of background. Absolute subset 
cell numbers were calculated by mutiplying the percentage of the indicated 
subset as obtained by flow cytomentry and absolute lymphocyte number as 
determined by the hematocrit. 
General statistics. Significant differences among groups of samples in 
OTUs percentages, phylum or genus level abundances, as well as in SCFA 
fecal concentrations, were assessed by Mann-Whitney U tests. Where 
appropriate the paired version of the test was used. Kendall correlation test 
between SCFA or lymphocyte concentrations and the relative abundance of 
microbial groups was achieved using function cor.test (R package Stats). P 
values were corrected for multiple comparisons using the Benjamini-
Hochberg method; False discovery rate (FDR) < 0.05 were considered as 
statistically significant.
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4.2. II part: SCFAs effect in vitro on human DCs 
Human monocytes-derived DCs generation and culture. DCs were 
generated from peripheral blood mononuclear cells (PBMC) from three 
different healthy volunteers. The mononuclear cells were separated by Ficoll-
Hypaque density gradient centrifugation and subsequently CD14+ monocytes 
were isolated from PBMCs by negative selection using magnetic beads 
(Miltenyi Biotec, Germany), accordingly with manufacturer's instructions. 
Monocytes were cultured at 37°C in 5%CO2 in media supplemented with 
10% fetal bovine serum (FBS, Gibco) GM-CSF and IL-4 (50 ng/ml both, 
PeproTech) for 7 days to generate im-DCs and m-DCs, after LPS (100ng/ml, 
E.coli 055:B5) stimulation for the last 24h.  
SCFAs treatments. Before all the SCFAs treatment has been performed a 
7-AAD assay following the manufacturer's instructions to determine the 
concentration that does not affect on DCs viability and for the next steps has 
been chosen 1mM as final concentration for each SCFAs treatment. For both 
im-DCs and m-DCs the last 24h were used for the single exposure to acetate 
or butyrate or propionate (all purchased by Sigma-Aldrich). 
7-Aminoactinomycin apoptosis assay. Cells were stained with 7-
aminoactinomycin (Sigma-Aldrich), and subjected to flowcytometric analysis 
as described elsewhere (Telford, King, & Fraker, 1992). 
FACS analysis for DCs activation state.  Cells staining has been 
performed to assess the maturation stage of DCs using 100.000 cells for 
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each treatment and acquired 50.000 events on the live cells by LSR Fortessa 
(BD) at the CFFC (Core Facility for Flow Cytometry, Faculty of Health and 
Medical Sciences, University of Copenhagen) following their protocols and 
procedures. Anti human HLA-DR (PE, BD, clone L243), anti-human CD83 
(BV421, Biolegend, clone HB15e) and anti-human CD86 (APC, Biolegend, 
clone IT2.2) were used. FACS data were analyzed by FlowJo v7.0. 
LEGENDPlex and ELISA arrays. IL-6 production has been measured in 
the supernatants of DCs by ELISA using R&D kit. For simultaneous 
quantification of chemokines has been used the bead-based multiplex assay 
LEGENDPlex (BioLegend) and acquired by LSRFortessa (BD) at the CFFC. 
These two methods have been performed following the manufacturer's 
instructions.  
RNA extraction and Affymetrix array. RNA was isolated and purified 
using the RNesy kit (Quiagen) according to the manufacturer's instructions 
then was assayed for quantity with NanoDrop spectrophotometer 
(NanoDrop, Wilmington, DE). Equally amount of RNA derived from the three 
donors were mixed together, each treatment with its own corrispondent.  
Sample labelling, microarray hybridization and analysis. Using the 
WT_PLUS labelling kit (Affymetrix, Santa Clara) the total RNA was 
first reverse transcribed into double stranded cDNA, subsequently amplified 
using In Vitro Transcription. The cRNA were converted to cDNA, fragmented 
and end labeled with biotin (all according to the manufacturers instructions). 
The HTA 2.0 arrays were hybridized 16 h at 45°C and the arrays were 
scanned at a Affymetrix 3000 7G scanner. The raw data were RMA 
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normalized using the Affymetrix Expression Console Software ver 4.0. 
Transcriptome analysis. Global gene expression analysis was 
conducted using Affymetrix GeneChip® Human Transcriptome Array HTA 
2.0. containing 70.523 gene-level probe sets to detect known genes and 
ESTs, providing nearly a coverage of 285.000 full-length transcripts covered 
(>245.000 coding transcripts, 40.000 non coding transcripts, 339.000 probe 
sets covering exon-exon junctions) the expressed genes in the human 
genome (performed by AROS Applied Biotechnology A/S, Aarhus, 
DK). The array data were normalized using Robust Multichip Average (RMA) 
normalization as recommended by Bolstad et al.  (Boldstad, Irizarry, Astrand, 
& al., 2003). Significance of DEG (2-fold change, p <0.05) was assessed by 
ANOVA, and adjusted for multiple testing by estimating false discovery rates 
(FDR). Data visualisation, including principal component analysis (PCA), heat 
maps and clustering was performed in Qlucore Omics Explorer v.3.0 (Qlucore 
AB, Lund, Sweden). Functional analysis and network representation of DEG 
was performed in Ingenuity Pathway Analysis (IPA, Ingenuity® Systems). 
RNA isolation, reverse transcriptase-PCR and qPCR. Total RNA was 
isolated using RNeasy Mini Kit (Qiagen) and cDNA was transcribed using the 
High Capacity cDNA Reverse Transcription Kit followed by PCR analysis using 
TaqMan® Gene Expression Assay method. All TaqMan probes were 
purchased by LifeTechnologies (GAPDH (Hs02758991_g1), FFAR2 
(Hs00271142_s1), FFAR3 (Hs02519193_g1), HCAR2 (Hs02341584_s1), 
HCAR3 (Hs02341102_s1), IL6 (Hs00985639_m1), IL12B (Hs01011518_m1). 
Amplification was performed in an Mx3000P real-time thermal cycler 
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(Stratagene) on standard settings. Data presented here was obtained from 
three independent experiments. Each experiment included three technical 
replicates. Results are presented as relative quantity to the control sample 
determined by the ddCt method, using GAPDH as reference gene and 
untreated im-DC as calibrator. 
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4.3. III part: Immune system reconstitution 
Patient features. Twenty three pediatric patients (9 males), with age 
ranging from 2 to 18 years (mean age 9 years), who underwent HSCT for 
onco-hematological disorders (16 subjects) and for hematological disorders 
(7 subjects), were enrolled at the Pediatric Bone Marrow Transplantation Unit 
of the Sant‟Orsola-Malpighi Hospital, Bologna, Italy. After provision of 
parent‟s informed consent, the study has been approved by the Ethical 
Committee of the Sant‟Orsola-Malpighi Hospital-University of Bologna (ref. 
number. 19/2013/U/Tess. 16 children were diagnosed with onco-
hematological disease and 7 of them hematological diseases.  9 children 
were affected by aGvHD and the disease was graded according to the Seattle 
grading system, 15 were alive without any evidences of disease during the 
period of 100 days considered, 5 died before blood was sampled and for 3 of 
them the relapse of disease occurred. Demographic and general clinical 
characteristics of the patients are summarized in Table 2. 
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Table 2: Anagraphical and general clinical informations of the enrolled patients - II part. 
Footnotes: F: female, M: Male, AML: acute myeloid leukemia, ALL: acute lymphoblastic 
leukemia, BDA: Blackfan Diamond anemia, ICL: idiopatic lymphocytopenia; Bu: busulfan ; 
TBI: total body irradiation; MUD: match unrelated donor, HLA: human leukocyte antigens; 
BM: bone marrow, Bu: busulfan, ATG: anti-thymocyte globulin, CSA: cyclosporine, MTX: 
methotrexate, PHEC: extracorporeal phoaferes, GvHD: Graft verus Host Disease, CMV: 
cytomegalovirus; EBV: Epstein Barr virus, ANED: alive no vidence of disease. 
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Lymphocytes population phenotyping. Whole peripheral blood (PB) 
samples were obtained by venipuncture and were collected every ten days, 
when it has been possible.  Each PB sample was received in heparinized tube 
(BD Vacutainer®) and used immediately in assays for the leucocyte 
counting, determined by SIEMENS ADVIA 2120 Hematology System. PBs 
were afterwards used for the immunophenotyping using a different mixes of 
monoclonal human-antibodies coniugated in different colors to detect all the 
subsets (all purchased from BD Biosciences): helper T cells (CD3+CD4+), 
cytotoxic T cells (CD3+CD8+), naive T cells (CDRA+CD4+/CD8+), memory T 
cells (CDR0+CD4+/CD8+), B cells (pan CD19+), natural killer (NK) cells 
(CD3-CD16+CD56+). After 20 minutes of staining the samples were treated 
with lysis buffer (custumized by S.Orsola-Malphighi Hospital Pharmacy) to 
reduce the red cells debris during the flow cytometry detection. 
In order to detect CD4+CD25++CD127-FoxP3+ T regulatory cells (Treg) and 
Th1, Th2, and Th17 has been used the protocols described in "T helper and 
T reg phenotyping" in I part: GM and SCFAs. 
Stained cells were analyzed by flow cytometry on FACSCanto™ II (BD) and 
data were analyzed by FACSDiva software (BD). Prior to the analysis, PMT 
values were adjusted running unstained or unstimulated cells to exclude 
autofluorescence and to control the intensity of background. Absolute subset 
cell numbers were calculated by mutiplying the percentage of the indicated 
subset as obtained by flow cytomentry and absolute lymphocyte number as 
determined by the hematocrit. 
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Statistical analysis. Patients were subdivided according to the type of HCT 
and aGvHD onset. The average values of each subset for each time point 
were compared between among all four groups to detect statistically 
significant differences by the Mann-Whitney two-sided. Significant 
differences among groups of samples for each lymphocyte subsets were 
assessed by ANOVA repeated-measurements. Further in order to evaluate all 
the time points as affecting variables on the recovery was used two-way 
ANOVA test for all the groups. 
All the charts and statistical tests were obtained and performed by GraphPad 
Prism 6.0.
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5. Results, discussion and conclusions 
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5.1. I part: Results and discussion 
5.1.1. GM and SCFAs variations in pediatric patients 
undergoing aHSCT 
 
HSCT procedures temporarily disrupt diversity, individual signature 
and SCFA production of the gut microbiota. 
 
The 16S rRNA gene-based phylogenetic profile of a total of 53 stool samples, 
with a minimum of 4 time points per subject (Figure 6), were analyzed by 
454 pyrosequencing of the V4 hypervariable region. A total of 384,106 reads 
were obtained, for a mean of 162 7,243±4,557 high-quality reads per 
subject. Reads were clustered in 6,895 operational taxonomic 163 units 
(OTUs, i.e. groups of sequences referring to the same species) at 97% of 
identity.  
In order to assess the overall impact of HSCT and all the standard associated 
procedures on the gut microbiota of pediatric patients we investigated the 
richness and diversity of the ecosystem in the pre-HSCT sample, in the first 
post-HSCT samples available (approximately corresponding to the 
engraftment date), and in the last available samples (as reference point for 
the patient complete recovery), which varies in sampling date due to 
differences in the individual path to recovery.  
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Figure 6: Clinical and sampling procedure. Schematic overview of the sampling time for each 
enrolled subject. HSCT (green), GVHD diagnosis (red) and fecal sample collection (black), 
with distance from HSCT expressed in days, are indicated. 
 
We observed HSCT causes in all subjects a profound disturbance of the gut 
ecosystem that can be measured in a loss of the 30% in average of the pre-
HSCT alpha diversity, expressed as Chao1 index for richness (mean ratio 
post-HSCT/pre-HSCT samples = 0.68, fdr corrected paired Mann-Whitney U 
test P = 0.0078). On the contrary, by comparing the  alpha diversity of the 
pre-HSCT samples with the last samples available for each subject, it was 
evident that the ecosystem recovered the initial amount of diversity both in 
aGvHD and in non-aGvHD subjects (mean ratio = 0.94) ( 
Figure 7 A-B). 
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Figure 7: GVHD-related microbiota signatures.  (A) Superimposition of the rarefaction curves 
of chao1 α-diversity metrics obtained for pre-HSCT samples (blue), GVHD samples (red), 
non-GVHD samples (dark green), as well as for the last available samples of the GVHD 
(orange) and non-GVHD (light green) subjects.  Dynamics of intestinal ecosystem diversity 
and variability shown by Chao1 index (B), and the variability among subjects (beta-diversity) 
expressed as weighted Unifrac distance (C). 
 
 
The mean value of weighted UniFrac distances among pre-HSCT samples 
was significantly lower than that obtained among post-HSCT samples 
(P<0.001), demonstrating an increase of the inter-subject gut microbiota 
diversity after transplantation. On the other hand, the last available samples 
showed a comparable degree of inter-subject diversity respect to pre-HSCT 
samples, further suggesting a progressive ecosystem recovery following 
HSCT ( 
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Figure 7 C). 
The dramatic events surrounding HSCT (immunological reconstruction above 
everything else, but also the prolonged fasting, antibiotic usage and other 
drugs administration) have been also associated to a loss of the individual 
signature of the GM composition.  
 
Supplementary Fig. S2. Loss of individual signature in gut microbiota composition. A. Hierarchical Ward-linkage 
clustering based on the Eisen distance between OTU count profiles. Samples from the same subjects are marked by 
colors (see legend). B. Weighted UniFrac distance PCoA of the fecal microbiota of all enrolled subjects. Percentage of 
variance in the dataset shown by the second and third principal component (PC) is reported. Samples from the same 
subjects are marked by colors. 
 
 
Figure 8: Loss of individual signature in gut microbiota composition. (A) Hierarchical Ward-
linkage clustering based on the Eisen distance between OTU count profiles. (B) Weighted 
UniFrac distance PCoA of the fecal microbiota of all enrolled subjects. Percentage of variance 
in the dataset shown by the second and third principal component (PC) is reported. 
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In order to quantify the effect of this upsetting event on the ecosystem 
architecture, we quantified the loss and subsequent recovery of OTU 
detected. HSCT was associated to a loss of the individual signature of the gut 
microbiota composition - samples from the same subjects did not cluster 
together in multivariate analyses (Figure 8 A-B). Indeed, only 8.3±4.9% of 
the OTUs in the pre-HSCT samples were conserved in the post-HSCT 
samples, a very small number of which “survived” through the last available 
samples of each subject (2.3±2.6% of the OTUs in the pre-HSCT samples), 
mostly assigned to the phyla Firmicutes (66.7%) and Bacteroidetes (27.5%). 
A small percentage of OTUs was under the limit of detection in the post-
HSCT samples but “reappeared” in the last available samples (5.9±4.7%); 
again, these sequences were assigned mostly to Firmicutes (73.6%).  
The 89.3±4.6% of the OTUs in the post-HSCT samples was new with respect 
to the pre-HSCT ecosystem, but 80.6±9.9% of those was only transient (i.e. 
not present in the last available sample of each patient). The fecal microbiota 
of the last available sample of each subject (i.e. taken at least 51 days after 
HSCT) was made for 86.1±9.7% of OTUs that were not present in the pre-
HSCT samples in both aGvHD and non-aGvHD patients (Figure 9).  
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Figure 9: Individual trajectory of microbiota profiles at family level for each enrolled subject. 
Relative abundance profiles are plotted on a timeline (weeks) with indication of HSCT (grey 
triangle) and eventual aGvHD diagnosis (red triangle). 
 
 
aGvHD-associated gut microbiota signatures 
 
In order to highlight peculiarities of the post-HSCT reconstruction process of 
the gut microbiota in subjects developing and non-developing aGvHD, the 
respective gut microbiota temporal trajectories were constructed and 
compared. To this aim, samples were grouped in four time intervals: (I) pre-
HSCT; (II) 0-35 days after HSCT (interval in which engraftment occurred 
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and, in our study, the diagnosis of the aGvHD was performed); (III) 35-65 
days after HSCT; (IV) >65 days after HSCT. 
PCoA analysis of the weighted UniFrac distances showed that samples from 
aGvHD subjects taken in the time interval between 0 and 35 days after 
HSCT, during which aGvHD emerged, clustered in the right part of the PCoA 
plot (P<0.05), showing that the aGvHD onset is associated to higher values 
on the PCo2 axis. This is even clearer when samples from each group are 
ordinated by PCo2 coordinates, as inspired by Smith et al. : aGvHD samples 
taken within the 0-35 days interval shows significantly higher values of PCo2 
coordinates than all the other samples (P<0.05).  
Interestingly, PCo2 was positively correlated (P<0.05) to members of the 
Enterococcus genus and unassigned Clostridiales, while Faecalibacterium and 
Ruminococcus showed a negative correlation with PCo2 (P<0.05). This 
suggests that aGvHD involves the overgrowth of Enterococcus and 
Clostridiales and a correspondent decrease of Faecalibacterium and 
Ruminococcus. Confirming these finding, Enterococcus members were found 
in significantly higher relative abundance in aGvHD samples, within 0-35 
days after HSCT, with respect to non-aGvHD samples (median 1.9% for 
aGvHD, 0.01% for non-aGvHD; P=0.016); Enterococcus abundance in this 
time interval was also almost significantly higher than in pre-HSCT samples 
of aGvHD subjects (median 0.03%, P=0.06), confirming the association with 
the aGvHD diagnosis (data not showed).  
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An opposite trend was found for the known health-promoting 
Faecalibacterium in aGvHD subjects (median values: pre-HSCT 12.5%, 0-35 
days 0.5%; P=0.06), but not for non-aGvHD subjects. 
To better understand the capability of aGvHD to affect the overall structure 
of the microbiota, phylum-level temporal dynamics of gut microbiota in non-
aGvHD and aGvHD subjects were constructed. Samples collected >65 days 
after HSCT were not taken into account in this analysis because they were 
available only for a small subset of subjects.  
Different trends emerged for the two most abundant phyla in the intestinal 
ecosystem: Firmicutes and Bacteroidetes. aGvHD subjects showed a drop in 
Firmicutes abundance after HSCT, then they recovered higher abundances of 
Firmicutes than the initial ones; such distinctive trend was not observed in 
non-aGvHD subjects (Figure 10 A). More interesting, aGvHD subjects showed 
lower abundances of members of the Bacteroidetes in all the considered time 
interval than non-aGvHD subjects, and the difference was significant in pre-
HSCT samples (median 0.11% for aGvHD, 14.8% for non-aGvHD; P=0.05) 
(Figure 10 B). 
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Figure 10: Phylum-level gut microbiota 
temporal dynamics. Box plots of relative 
abundance of Firmicutes (A) and 
Bacteroidetes (B) for aGvHD (grey) and 
non-GvHD (white) subjects at three time 
intervals (pre-HSCT, 0-35 days and 35-65 
days after HSCT). 
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5.1.2. GM and SCFAs 
 
In order to obtain an indication of the maintenance or disruption of the 
functionality of the intestinal ecosystem, we quantified the short chain fatty 
acids content in fecal samples. The fecal amount of short chain fatty acids 
decreased by 76% after HSCT in both aGvHD and non-aGvHD subjects 
(mean ratio post-HSCT/pre-HSCT 0.23, fdr-corrected paired Mann-Whitney U 
test P=0.016). Acetate and butyrate decreased by 64 and 77%, respectively 
(mean ratio post-HSCT/pre- HSCT 0.17 and 0.16, respectively; fdr-corrected 
paired Mann-Whitney U test P=0.023 and 0.011, respectively), while 
propionate was the most reduced, with a mean loss of 86% in the first post- 
HSCT sample with respect to the pre-HSCT (mean ratio post-HSCT/pre-HSCT 
0.14, fdr-corrected paired Mann-Whitney U test P=0. 201 018). By 
comparing the short chain fatty acids amount in pre-HSCT samples with the 
last samples available for each subject, the gut microbiota seemed to recover 
the initial functionality both in terms of total short chain fatty acids (mean 
ratio 1.23; paired Mann-Whitney U test P=0.73) and propionate (mean ratio 
1.09; paired Mann-Whitney U test P=0.82) production. 
 
Indeed, the relative abundances of Bacteroides and Parabacteroides in the 
pre-HSCT samples were found significantly correlated with the amount of the 
immunomodulatory SCFA propionate (Kendall tau correlation coefficients: 
Bacteroides-propionate, 0.61, P = 0.028; Parabacteroides-propionate, 0.61, P 
= 0.025). Also, pre-HSCT samples in subject who did not develop aGvHD 
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tended to show higher amounts of both total SCFA (mean 4.3 µmol/g vs 2.5 
µmol/g, P = 0.1) and propionate (mean 0.56 µmol/g vs 0.27 µmol/g, P = 
0.06) ( 
Figure 11). 
 
 
 
 
Figure 11: Pre-HSCT compositional and functional microbiota signatures that could exert a 
protective role against GVHD. (A) Pre-HSCT relative abundance of OTUs assigned to the 
genus Bacteroides in GVHD (grey) and non-GVHD (white) subjects. (B) Pre-HSCT relative 
abundance of OTUs assigned to the genus Parabacteroides in GVHD (grey) and non-GVHD 
(white) subjects. (C) Pre-HSCT fecal concentration of propionate (µmol/gr of feces) in GVHD 
(grey) and non-GVHD (white) subjects. (D) Pre-HSCT fecal concentration of total SCFA 
(µmol/gr of feces) in GVHD (grey) and non-GVHD (white) subjects.
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5.1.3. The pre-HSCT gut ecosystem could influence the 
immune system. 
 
Among the 53 available samples five groups were defined: (I) pre-HSCT 
samples of all subjects (n = 10);  (II) non-GVHD samples, including all 
samples from the 5 non-GVHD patients with the exception of pre-HSCT 
samples and the last available sample of each subject (n = 12); (III) GVHD 
samples, including all samples from the 5 GVHD patients with the exception 
of the pre-HSCT samples and the last available sample of each subject (n = 
21); (IV) last samples of non-GVHD subjects (n = 5); (V) last samples of 
GVHD subjects (n = 5).  
Pre-HSCT samples were significantly enriched in OTUs assigned to the 
genera Blautia (mean 11% in pre-HSCT group, 0.8% in non-aGvHD, 4.5% in 
aGvHD; pre-HSCT vs. non-aGvHD, P < 0.01; pre-HSCT vs. aGvHD, P = 0.04) 
and Faecalibacterium (mean 17% in pre-HSCT group, 5.1% in non-aGvHD, 
5.5% in aGvHD; pre-HSCT vs. non-aGvHD, P = 0.04; pre-HSCT vs. aGvHD, P 
< 0.01), with respect to both aGvHD and non-aGvHD samples. Analogous 
tendency was found for the genus Roseburia (mean 8.7% in pre-HSCT 
group, 0.7% in non-aGvHD, 2.9% in aGvHD; pre-HSCT vs. non-aGvHD, P = 
0.09; pre-HSCT vs. aGvHD, P = 0.2). For these genera no significant 
differences were found between pre-HSCT and the last available samples of 
each subject, both in aGvHD and non-aGvHD cases. Both Faecalibacterium 
and Blautia tended to positively correlate with Treg and Th17 lymphocytes 
population counts in peripheral blood (Kendall tau coefficients: Blautia-Treg, 
0.22, P = 0.03; Blautia-Th17, 0.24, P = 0.02; Faecalibacterium-Treg, 0.25; P 
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= 0.01). Moreover, Faecalibacterium was the most frequent genus among 
those who decreased until under the detection limit after HSCT but were 
present in the last available samples of each subjects (17.1% of the 
“reappearing” OTUs, in 8 out of 10 subjects). 
 
 
Figure 12: Early recovery of lymphocytes populations in peripheral blood after HSCT. Box 
plot of the Th1, Th2, Th17 and Treg count binned in 3 intervals, from day 0 to 25 (white), 
from day 26 to 50 (light grey) and from 50 to 100 (dark grey). 
 83 
5.2. I part: Conclusions 
 
In this study we demonstrated, to our knowledge for the first time, that in 
pediatric patients allogeneic HSCT is associated to a profound modification of 
the gut bacterial ecosystem with a disruption of its mutualistic asset. The 
pre-HSCT GM structure of the enrolled subjects well approximated the 
commonly reported healthy-like profile  (Eckburg, Bik, Bernstein, & al., 2005)  
(Dethlefsen, Huse, Sogin, & al., 2008), in terms of diversity and relative 
abundance of the most abundant Firmicutes, Bacteroidetes and 
Actinobacteria families. Moreover, the pre-HSCT GM was found to be efficient 
in terms of SCFA production, which is the biomarker of GM functionality 
(Tremaroli & Bachked, 2012). After HSCT, we witnessed a disruption of the 
gut ecosystem with only a very small percentage of conserved OTUs and an 
“invasion” of new OTUs. This deep modification was accompanied by a 
marked reduction in the ecosystem diversity, confirming the available 
literature on adult patients  (Holler, Butzhammer, Schid, & al., 2014)  (Taur, 
Xavier, Lipuma, & al., 2012), and a damage in the mutualistic layout of the 
microbiota, as shown by the impaired transgenomic host-microbiota 
metabolism – here measured as the ability of the gut microbiota to produce 
SCFA– found in post-HSCT samples. These dramatic shifts bring to a loss of 
the individual fingerprint, with samples from the same subject that are not 
more compositionally similar to each other than samples from different 
patients. The great majority of the newly acquired phylotypes is only 
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temporarily invading the ecosystem and is replaced later on during the 
ecosystem recovery.   
After approximately 2 months from the day of HSCT, the ecosystem recovers 
the initial richness and metabolic capability, as well as a phylogenetic 
architecture that mirrors a healthy-like asset, as demonstrated by the ability 
of well-known gut mutualists, such as Faecalibacterium, Roseburia and 
Blautia, to regain abundances comparable to the pre-HSCT values after the 
strong HSCT-induced decrease. Interestingly, a small percentage of OTUs 
resisted HSCT and are conserved throughout the whole longitudinal survey, 
or lower their abundance under the detection limit as a consequence of the 
ecosystem upsetting and “reappeared” later on. These persisting species 
could act as “founders” to reconstruct a healthy-like ecosystem once 
conditions allow. Indeed, Bacteroides species, that were the most 
represented among the persisting ones, are known to be able to penetrate 
the colonic mucus and reside deep within crypt channels where they act as a 
bacterial reservoir to maintain long-term colonization or repopulate the gut 
after ecosystem disruption  (Lee, Donaldson, Mikulski, & al., 2013). 
Moreover, they are recognized as the most stable members of GM over 
lifetime  (Faith, Guruge, Charbonneau, & al., 2013), probably thanks to their 
greater adaptability to different energy sources with respect to other 
symbionts, and are known to be able to utilize mucins as a fermentation 
substrate  (Fisbach & Sonnenburg, 2011), an ability that could be of use 
during the prolonged post-HSCT fasting period. Finally, Bacteroidetes were 
found to be only marginally affected by chemotherapy in oncology patients 
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(Zwielehner, Lassl, Hippe, & al., 2011), confirming their resilience and 
capability of niche adjustment even in prohibitive conditions. 
According to our data, aGvHD and non-aGvHD subjects showed differences 
in the process of gut microbiota recovery. aGvHD samples showed a lower 
diversity, confirming recent data obtained in adults and mice  (Jenq, Ubeda, 
& Taur, 2012), and higher abundances of unassigned OTUs, that could be 
indicative of a higher invasion of the ecosystem by opportunistic bacteria. 
Moreover, aGvHD samples were characterized by higher abundances of 
Granulicatella and Enterococcus, the latter confirmed in adults by Holler et al.  
(Holler, Butzhammer, Schid, & al., 2014).  
On the contrary, non-aGvHD subjects showed a higher abundance of 
members of the phylum Bacteroidetes (Bacteroides and Parabacteroides) not 
only after HSCT but also in the pre-HSCT composition, letting hypothesize 
that these gut persisters can somehow contribute in protecting from aGvHD. 
Indeed, these microbes are known to produce propionate from dietary fiber  
(Fisbach & Sonnenburg, 2011), and were correlated with the pre-HSCT fecal 
concentration of propionate in this study.  
Propionate is generated in the gut but can enter the blood circulation and 
disseminate systemically, where it exerts immunomodulatory functions, such 
as promotion of extrathymic Treg generation and homing to the gut  (Arpaia, 
Campbell, Fan, & al., 2013), as well as enhancement of hematopoiesis of 
dendritic cell precursors with a low ability to activate the allergy-related Th2 
cells  (Trompette, Gollwitzer, Yadava, & al, 2014), that might contribute to 
aGvHD protection. 
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The challenging nature of the enrollment of ill children, for whom parents‟ 
consent and strong motivation are required, and the difficulty to obtain 
compliance for the collection of fecal samples during a highly sensitive period 
of illness, limited the number of patients studied in the present paper, that 
should be considered as a pilot study in the field. Nonetheless, the relevance 
of this study, as well as the importance of future development of the same 
approach, become evident considering the increasing number of pediatric 
patients who can be cured by allogeneic HSCT and the relevance of aGvHD 
as a potential life-threatening event limiting this procedure  (Dignan, Potter, 
Ethell, & al., 2013). 
Our study indicates, with the needed caution, that the pre-existing GM 
structure can be protective against aGvHD onset, and we propose a model in 
which specific gut mutualist microorganisms, belonging to Bacteroidetes 
phylum and able to produce immunomodulatory protective metabolites, 
resist the ecosystem damages by HSCT and can act as founders for the 
ecosystem recovery, preventing the occurrence of future complications. In 
this scenario, it could be important to seek for strategies to reduce the 
probability of aGvHD in pediatric patients by manipulating the pre-HSCT 
dietary habits. Indeed, diet might be the most important determinant of the 
pre-HSCT microbiota composition and functionality, and indirectly control the 
production of immunomodulatory and protective metabolites, such as 
propionate (Biagi, Zama, Nastasi, & al., 2015).
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5.3. II part: Results and discussion 
5.3.1. Immature and mature DCs generation and SCFAs 
treatments 
 
DCs were generated from monocytes isolated from peripheral blood 
mononuclear cells (PBMC) of three different healthy donors. The 
mononuclear cell fraction was isolated by Ficoll-Hypaque density gradient 
centrifugation. CD14+ monocytes were isolated from PBMC by negative 
selection using MACS magnetic beads and were cultured in media 
supplemented with GM-CSF (50ng/ml) and IL-4 (50 ng/ml) for 6 days. 
Immature dendritic cells (im-DCs) were treated with 1mM of sodium acetate 
(im-DC_A), or sodium butyrate (im-DC_B), or sodium propionate (im-DC_P) 
for the last 24h of culture in order to investigate the effect of the these three 
SCFAs on the maturation process; mature dendritic cells (m-DCs) were 
exposed to SCFAs in the same way and for the same time period together 
with lipopolysaccharide (LPS) (100ng/ml, E.coli 055:B5) obtaining the 
following treatments: m-DC_A, m-DC_B and m-DC_P; im-DC SCFA-untreated 
(im-DCs) and m-DCs SCFAs-untreated (m-DCs) were used as controls for the 
immature and mature state, respectively. The viability of DCs under the 
different treatments was examined, and no increase in non-viable cells 
numbers was observed when cells were exposed to 1 mM SCFA (Figure 13).  
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Figure 13: 7AAD vitality assay shows the percentage of non viable DC cells after each 
exposure at different concentrations with acetate or butyrate or propionate. 
 
In order to validate the DCs maturation state have been performed flow 
cytometry analysis with particular attention on HLA-DR, CD83 and CD86, 
surface markers that are usually overexpressed only on the surface of m-DCs 
but not on im-DCs (Figure 14 A). 
 
 
Figure 14: (A, B) Flow cytometry DCs gating and SCFAs effect. The figure is representative 
of the gating strategy for DCs for HLA-DR, CD83, and CD86 markers for both im-DCs and m-
DCs. It also shown an example of SCFAs effect on im-DCs and m-DCs. 
 
 
For all three donors monocytes-derived DCs has been checked for the 
maturation state through all the eight treatments considered to assess the 
reliability for the next steps. As expected, their surface expression was 
increased after the addition of LPS into the culturing media (Figure 14 A).  
Next we investigate the impact of SCFAs on DCs maturation makers. 
Interestingly, the presence of SCFA did not affect the expression of either  
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HLA-DR or CD86, whereas the LPS-induced expression of CD83 was 
significantly reduced by the exposure to both sodium butyrate and sodium 
propionate when compared to normally matured DCs (unpaired t test with 
Welch's correction, p-value: 0.025 and 0.01, respectively) (Figure 14 B) 
(Figure 15). 
 
 
Figure 15: Rate of the DC's activation analyzed by FACS shown as mean fluorescence 
intensity (MFI). Each bar corresponds to the average between three different donors values 
 SD; (*) P value<0.05.  
 
 
5.3.1. SCFAs receptors expression by DCs 
 
Several G-protein-coupled receptors (GPCRs), including Gpr41 (FFAR3), 
Gpr43 (FFAR2), Gpr109a (HCAR2), and Gpr109B (HCAR3) have been shown 
to be activated or sensitive to SCFAs (Soga, Kamohara, Takasaki, & al., 
2003)  (Taggart, Kero, Gan, & al, 2005)  (Irukayama-Tomobe, Tanaka, 
Yokomizo, & al., 2009). 
To determine the expression pattern of SCFAs receptors on human DCs, we 
performed qPCR assays for these genes using MCF-7 cell line as a positive 
control as it expresses high level of FFAR2 and much lower levels of FFAR3 
gene (Yonezawa, Kobayashi, & Obara, 2007). As shown in Figure 16 A we 
found that basically human monocyte-derived im-DCs express FFAR2 and 
FFAR3 at lower and higher level, respectively, compared to the positive 
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control. In contrast we observed very low levels of HCAR2 and HCAR3 
expression on MCF-7 cells and even higher for DCs. Interestingly, the 
expression of HCAR2 and HCAR3 is affected by the LPS stimulation thus that 
the m-DCs do not express anymore those receptors. Afterwards the 
treatments with butyrate or propionate we observed a recovery of these 
receptors expression, not observed after acetate exposure Figure 16 B. This 
evidence opens new perspectives on the regulation of SCFAs receptor 
expression on DCs respect other cellular types. 
 
 
Figure 16: Gene expression of SCFAs receptors  (A) FFAR2, FFAR3, HCAR2, and HCAR3 on 
MCF-7 and DCs  and (B)  HCAR2 and HCAR3 only on DCs un-/treated with acetate, 
propionate, or butyrate. 
 
 
 
5.3.2. SCFAs effect on immature and mature DC. 
 
In order to investigate the DCs gene expression profile have been used total-
RNA extracted from the above mentioned samples and analyzed on 
Affymetrix GeneChip® Human Transcriptome Array HTA 2.0.  
Were used 70.523 probe sets to detect known genes and ESTs, providing 
nearly a coverage of 285.000 full-length transcripts covered (>245.000 
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coding transcripts, 40.000 non coding transcripts, 339.000 probe sets 
covering exon-exon junctions) the expressed genes in the human genome.  
The array data were normalized using Robust Multichip Average (RMA) 
normalization as recommended by Bolstad et al.  
Significance of DEG (2-fold change, p <0.05) was assessed by ANOVA, and 
adjusted for multiple testing by estimating false discovery rates (FDR). In 
order to characterize those genes specifically affected by SCFAs the 
transcription profiles have been normalized by subtracting the genes 
similarity affected by unconditioned culture medium from genes affected by 
SCFAs in the case of im-DCs, and by subtracting the gene similarity affected 
by LPS-conditioned medium from genes affected by SCFAs together a LPS-
medium in the case of m-DCs. Then data were visualized in Qlucore Omics 
Explorer 3.0 (Qlucore AB), and network analysis was performed by Ingenuity 
Pathway Analysis (IPA, Qiagen). 
Comparing untreated im-DCs to untreated m-DCs revealed 1752 differentially 
expressed genes (DEG) (cut off criteria: >2-fold change, p<0.05) due to the 
maturation stimuli, while exposure to SCFAs resulted in the modulation of the 
m-DC gene expression response to LPS and in a slightly variation of im-DC 
trascriptome (Figure 17).  
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Figure 17:  Heat-map and unsupervised hierarchical clustering based on the top 200 
differentially expressed genes (DEG). 
 
 
 
Visualization of the data by an unsupervised clustering model (principal 
component analysis) [PCA] further supported the specific and stronger effect 
of butyrate and propionate on the clustering of expressed genes of m-DCs. 
The same behavior was observed for im-DC, with an overall lower variation 
in the expression profile. In contrast, the effect of acetate treatment is 
similar to the one shown by untreated controls (both for im-DC and m-DCs) 
(Figure 18). 
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Figure 18: PCA representing the individual effect exerted by acetate, butyrate, and 
propionate on im-DC and m-DC among 737 most variables genes. 
 
Indeed, the transcriptome analysis revealed that butyrate and propionate, 
more than acetate, elicit a specific change of response by both treated im-
DCs, and m-DCs; the general effect exerted by SCFAs can be ranked as: 
acetate < propionate < butyrate. In fact, acetate only induced minor 
changes in gene expression (8 DEG) in im-DCs, and none in m-DCs. 
Further, acetate seems not to share many affected genes with either 
butyrate (none and 3, up- and down-regulated genes, respectively) or 
propionate (2 and 0, respectively) in immature DCs. Regarding m-DCs, 
acetate treatment also has the same weak effect on mature DCs not sharing 
any genes in common  with butyrate and propionate. Propionate affects few 
genes (14 up-, and 10 down- regulated) while butyrate shows the biggest 
effect up-regulating 467 and down-regulating 327 genes. Furthermore, 
butyrate and propionate treatments share the largest number of affected 
genes 233 up- and 44 down-regulated among all the comparisons mentioned 
above (Figure 19). 
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Figure 19: Venn 
diagrams representing 
the up-(green) and 
down-(red) regulated 
genes by im-DC and m-
DC after exposure to A 
(acetate) or B 
(butyrate) or P 
(propionate). 
 
 
 
Ingenuity pathway analysis (IPA) based on these DEG identified no 
significant networks or pathways involved by acetate treatments magnifying 
the effect exerted by butyrate and propionate. In fact, IPA analysis revealed 
"granulocytes adhesion and diapedesis" as one of the top altered canonical 
pathway involved by the exposure to butyrate, for both im-DC and m-DC; 
the same has been proposed by IPA regarding the effect of propionate 
shown only by m-DC. Indeed looking at the down-regulated genes have 
been shown that the expression of some of the chemokines have been 
affected by butyrate and propionate, especially in the mature stage of DCs 
(Table 3). The top molecules down-regulated in the m-DC cells after butyrate 
treatment when compared to the untreated control are CXCL9 (-5.8), CXCL10 
(-5.0), CXCL11 (-5.3), CCL19 (-5.4) (Table 4) and the top molecules that are 
affected by propionate treatment includes CXCL9 (-2.0), CCL19 (-1.7), IL-6 (-
2.3), IL12B (-2.0) (Table 4) indicating an overall anti-inflammatory effect 
exerted by both SCFAs. Among the up-regulated genes by butyrate in both 
im-DCs and m-DCs we noticed Aldh1a (aldehyde dehydrogenase 1 family, 
member 1), that codes for an enzyme involved in metabolizing retinoic acid 
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(RA) and that exerts an immunomodulatory role in mice (Singh, Gurav, 
Sivaprakasam, & al, 2014). 
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Comparison 
Top canonical 
pathway 
P value 
Top diseases and bio-
functions 
P value 
num. 
molecules 
Top networks Score 
m-DCs vs im-DCs 
dendritic cell 
maturation 
1.57E-16 immunological diseases 
9.25E-39 - 
6.83E-08 
486 
Cellular Movement, Hematological 
System Development and Function, 
Immune Cell Trafficking 
34 
im-DCs_A vs im-DC no effect       
im-DC_B vs im-DC 
granulocyte adhesion 
and diapedesis; 
agranulocyte adhesion 
and diapedesis 
3.48E-09; 
5.63E-09 
Inflammatory response 
4.64E-16 - 
2.81E-04 
90 
Antigen Presentation, Lipid Metabolism, 
Small Molecule Biochemistry 
33 
im-DCs_P vs im-DCs eicosanoid signaling 1.15E-04 
Inflammatoy response; 
hematological system 
development and function; 
cell-to-cell signaling and 
interaction 
5.9E-08 - 
1.16E-02; 
2,44E-06 - 
1.16E-02; 
2.4E-06 - 
1.2E-02 
14; 15; 16 
Cardiovascular Disease, Inflammatory 
Response, Cell-To-Cell Signaling and 
Interaction 
32 
m-DCs_A vs m-DCs no effect       
m-DCs_B vs m-DCs 
granulocyte adhesion 
and diapedesis; role of 
Pattern Recognition 
Receptors in 
Recognition of Bacteria 
and Viruses; dendritic 
cell maturation 
6.4E-13; 
3,3E-10; 
9.48E-10 
Cell movement; Cellular 
function and maintenance; 
hematological system 
development and function 
1.38E-25 - 
2.9E-06; 
4.88E-25 - 
2.16E-06; 
4.4E-27 - 
2.73E-06 
257; 284; 
278 
DNA Replication, Recombination, and 
Repair, Nucleic Acid Metabolism, Small 
Molecule Biochemistry 
39 
m-DCs_P vs m-DCs 
granulocyte adhesion 
and diapedesis; 
dendrititc cell 
maturation; graft-
versus-host disease 
signaling 
7.32E-12; 
1.05E-10; 
1.12E-07 
Immunological disease; 
inflammatory response;  cell-
to-cell signaling and 
interaction; hematological 
system development and 
function 
3.82E-20 - 
1.40E-04; 
4.33E-19 - 
1.62E-04; 
4.04E-19 - 
1.9E-04;1.76E-
19 - 1.9E-04 
102; 118; 
116; 117 
Cellular Function and Maintenance, 
Cellular Development, Hematological 
System Development and Function 
30 
m-DCs_B vs m-
DC_A 
granulocyte adhesion 
and diapedesis; role of 
Pattern Recognition 
Receptors in 
Recognition of Bacteria 
and Viruses; dendrititc 
6.7E-13; 
9.62E-11; 
4.93E-09 
Inflammatory response; 
Cellular function and 
maintenance; hematological 
system development and 
function 
8.31E-24 - 
1.14E-06; 
1.22E-27 - 
7.33E-07; 
7.69E-31 - 
1.23E-06 
275; 278; 
268 
Cell Morphology, Cellular Development, 
Embryonic Development 
38 
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cell maturation 
m-DCs_P vs m-
DC_A 
granulocyte adhesion 
and diapedesis; 
dendrititc cell 
maturation; 
Communication 
between Innate and 
Adaptive Immune Cells 
2.11E-13; 
1.47E-08; 
2.17E-08 
Immunological disease; Cell-
to-cell signaling and 
interaction; immune cell 
trafficking; hematological 
system development 
6.04E-22 - 
1.15E-04; 
2.72E-18 - 
1.49E-04; 
1.44E-19 - 
1.5E-04; 
1.48E-18 - 
1.5E-04 
88; 95; 76; 
100 
Cell-To-Cell Signaling and Interaction, 
Hematological System Development 
and Function, Immune Cell Trafficking 
30 
m-DCs_P vs m-
DC_B 
granulocyte adhesion 
and diapedesis; 
agranulocyte adhesion 
and diapedesis 
6.21E-11; 
1.52E-10 
Immunological disease; Cell-
to-cell signaling and 
interaction; hematological 
system development 
2.57E-24 - 4E-
05; 2.54E-16 - 
7E-05; 2.54E-
16 - 6.8E-05 
88;75;77 
Antimicrobial Response, Inflammatory 
Response, Infectious Disease 
37 
 
Table 3: IPA analysis report relative to each comparison. 
 
 98 
 
Comparison Top molecules up-regulated log ratio Top molecules down-regulated log ratio 
m-DCs vs im-DCs 
CXCL11, CXCL10, CXCL9, IFI44L, 
IL2RA, IDO1.. 
7.6, 7.4, 7, 6.0, 
5.5, 5.2 
F13A1, SCN9A, CLEC10A, MRC1, 
CD209.. 
-5.7, -5.4, -5.0, -5.0, -4.5 
imDCs_A vs im-DC CXCL10, CCL2, CD40, IL12B, IL1A.. 
1.6, 0.6, 0.5, 0.5, 
0.4 
PTPLB, TLR7, TLR8.. -1.0, -0.5, -0.3 
imDC_B vs im-DC 
MIR3143, mir-146, IL1B, 
IL3RA,ALDH1A1.. 
3.5, 3,3, 3.0, 3.0, 
2.5 
NFXL1, PRR11, PTGER3, MAP2K6, 
CXCL13.. 
-3.3, -2.2, -2.2, -2.2, -2.0 
imDCs_P vs im-DCs CCR2, LRP1, CCL1, CXCL10.. 1.8, 1.7, 1.6, 1.5 NFXL1, IFI6, PRR11, PTGER3.. -1.5, -1.5, -1.2, -1.2 
mDCs_A vs mDCs -- -- -- -- 
mDCs_B vs mDCs 
MRC1, STEAP4, MPEG1, IL1A, CD36, 
IL1RAP, HCAR2,ALDH1A1.. 
4.8, 4.6, 4.2, 4.0, 
3.8, 3.7, 3.5, 2.3 
CXCL9, CXCL11, CXCL10, CCL19, 
GBP4, IL12B, HERC6, BRIP1, ANKRD22, 
CYP7B1.. 
-5.8, -5.3, -5.0, -4.0, -4.0, 
-3.4, -3.4, -3.3, -3.0, -3.0 
mDCs_P vs mDCs CD207, MRC1, CCL1, IL1RAP 3.3, 3.2, 3.2, 3.0 
TNFSF18, IL6, CXCL9, IL12B, TNFSF4, 
HERC6, CCL19.. 
-2.6, -2.3, -2.0, -2.0, -2.0, 
-1.7, -1.7 
mDCs_B vs mDC_A 
STEAP4, MRC1, IL1A, CD36, MPEG1, 
IL1RAP, HCAR2, HCAR3 
4.5, 4.5, 4.0, 4.0, 
3.6, 3.5, 3.4, 3.3 
CXCL9, CXCL11, CXCL10, CCL19, 
HERC6, IL12B.. 
-5.5, -5.3, -5.2, -4.0, -3.3, 
-3.3 
mDCs_P vs mDC_A 
CCL1, MRC1, CD207, IL1RAP, 
HCAR2, CCR1 
3.0, 2.8, 2.8, 2.7, 
2.3, 2.3 
CXCL9, IL6, IL12B, TNFSF18, GBP4, 
TNFSF4, HERC6, CCL19.. 
-2.0, -1.9, -1.7, -1.7, -1.6, 
-1.6, -1.6 
mDCs_P vs mDC_B 
CXCL10, CXCL11, CXCL9, 
ANKRD22, CCL13, CCL2, CCL19 
3.8, 3.8, 3.4, 2.8, 
2.55, 2.5, 2.4 
IL1A, GATM, CD70, STEAMP4, MMP10.. -3.0, -2.6, -2.0, -2.0, -2.0 
 
Table 4: Top molecules up- and down-regulated shown by each comparison and relative log ratio.
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5.3.3. Immunomodulatory effects of butyrate and propionate 
on m-DCs. 
 
The transcriptome analysis revealed that butyrate and propionate, but not 
acetate, exert an immunomodulating effect on mature DCs. For LPS-treated 
DCs the butyrate effect is most pronounced in “normalizing” the gene 
expression levels back to those observed in the PBS-treated DCs down-
regulating the CXCL9, CXCL10, CXCL11, and IL12B genes.  The propionate 
effect is similar but not as strong as the butyrate one and likewise it 
decreases the expression of CXCL9, IL6 and IL12B. To assess the microarray 
data we performed qPCR for IL6 and IL12B and ELISA assays for IL6. Both 
butyrate and propionate significantly reduced LPS-induced IL-6 mRNA 
expression (P-value <0.05) (Figure 20 A), whereas the effect of on IL-12B 
gene expression was significant (P-value<0.05) only after butyrate treatment 
but not for propionate, as seen in (Figure 20 B).  
 
 
Figure 20: qPCR (A, B) and ELISA (C) profile by m-DCs treated with acetate, butyrate, 
propionate. Shown are the averages ± standard deviations (SD) (n=3); Mann-Whitney t 
test, *P < 0.05. 
 
The effect on LPS-induced IL-6 was confirmed by ELISA for IL-6 release by 
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mature DCs exposed to butyrate and propionate as protein levels were 
significantly reduced (P-value < 0.05, respectively) (Figure 20 C). 
Further, the chemokines secreted into the media were measured through 
LEGENDPlex  array confirming a significant reduction of CXCL9, CXCL10, 
and CXCL11 production after butyrate and propionate exposure by m-DCs 
(Figure 21 PanelA).   
In order to investigate deeper the effect of SCFAs on DCs chemokines 
pattern we measured ten chemokines by LEGENDplex array after the same 
treatments. This analysis revealed that im-DC are not responsive to the 
addiction of SCFAs instead of the mature DCs whose chemokines production 
change peculiarly depending on what SCFA is added into the media. As 
mentioned above, butyrate and propionate, but not acetate, significantly 
reduce the secretion of CXCL9, -10, -11 by m-DCs (Figure 21 Panel A). 
Further, CCL3 release is significantly reduced by acetate and propionate, but 
not by butyrate; CCL4 is reduced only by butyrate but not by acetate neither 
by propionate; CCL5 production decreases after butyrate and propionate 
exposure but is not modified by acetate (Figure 21 Panel B). CCL2, CCL11, 
CXCL11 are not significant affected by SCFAs and CXCL5 is not produced at 
all by m-DCs (Figure 21 Panel C).  
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Figure 21: Chemokines production profile by im-DCs and m-DCs treated with acetate, 
butyrate, propionate. Shown are the averages ± standard deviations (SD) (n=3); Unpaired t 
test with Welch's correction, *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. 
 
 
It's known that the chemokines CCL3, CCL4, CCL5 and CXCL10 are peculiarly 
secreted by m-DCs but not by imDC (Sallusto, Palermo, Lenig, & al, 1999) 
and from our assays has been seen the same trend confirming the 
maturation state of the DCs; interestingly, has been demonstrated that 
butyrate and proprionate affect on their secretion and thus on the normal 
maturation DC's chemokines pattern.  
We hypothised that the reduction of CCL3, CCL4 and CCL5 mediated by 
butyric and proprionate acids may impact the normal maturation of DCs and 
hence their ability to modulate the T cells polarization. 
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5.4. II part: Conclusions 
 
 
Human beings have been recently reconsidered as super-organisms in co-
evolution with an immense microbial community living in the in the 
gastrointestinal tract (GIT), the human intestinal microbiota (Gill, Pop, 
Deboy, & al., 2006)  (Ley, Hamady, Lozupone, & al, 2008). Its collective 
genome provides functional features that humans have not evolved by their 
own, and several of our metabolic, physiological and immunological features 
depend on the mutualistic association with our intestinal microbial 
community such as enhancing our digestive efficiency by degrading 
otherwise indigestible polysaccharides, influencing the synthesis and 
absorption of many nutrients and metabolites including short-chain fatty 
acids  (Neish, 2009)  (Lee & Marzamian, 2010). Further, the link between the 
immune system and the GIT microbial community is essential for the 
development, education and functionality of our immune system  (Garrett, 
Gordon, & Glimcher, 2010)  (Hooper & Macpherson, 2010). Dendritic cells 
behave as sentinels of the immune system and their function is to sample 
antigen in inflamed tissue and migrate to the local lymph nodes where they 
besides the presentation of  these antigens to T naive cells also produces 
cytokines, thus influencing the polarization into different T-helper-cell 
subsets eg. Th1, Th2 or Th17.  
In this study we hypothesized that SCFAs, secreted in to the gut and 
distributed through blood to tissues, have immunomodulatory effects on 
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human dendritic cells that, as APCs, have the ability to shape the immune 
system's response.  
DCs use specific receptors to sense and respond to bacterial metabolites. 
According to the literature, one largely used mechanism is via metabolite-
sensing GPCRs such as, GPR43, GPR41, and GPR109A, all of which can act 
as receptors for SCFAs. Indeed, many of the actions related to SCFAs, and 
linked to gut homeostasis, are ascribed to GPR43 and GPR109A that are also 
both expressed by inflammatory leukocytes (such as neutrophils and 
macrophages) and by Treg cells  (Smith, Howitt, Panikov, & al, 2013)  
(Singh, Gurav, Sivaprakasam, & al, 2014). However, SCFAs effects are not 
restricted to GPR43 and GPR109a, given that a recent study established a 
role for propionate and the SCFA receptor GPR41 in the generation of 
macrophages and DC precursors (Trompette, Gollwitzer, Yadava, & al, 2014).  
Here we observed that GPR43 and GPR41 are not expressed by human im-
DCs. Instead, these cells express relative high levels of GPR109A and 
GPR109B, indicating that these receptors more than the traditional ones, 
such as GPR41 and GRP43, can mediate the uptake by human DCs.  
These observations made us propose a new hypothesis, namely that human 
DCs use different SCFA receptors compared to the other immune cells e.g.  
macrophages. This hypothesis is supported by the fact that GPR109A has 
recently emerged as a major regulator of gut homeostasis binding the SCFAs 
butyrate but also the tryptophan metabolite nicotinic acid which anti-
inflammatory properties upon monocytes, macrophages and epitelial cells are 
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well known (Digby, Martinez, Jefferson, & al., 2012) (Gambhir, Ananth, 
Veeranan-Karmegam, & al., 2012).  
Besides, the analysis of the transcriptome revealed that butyrate and 
propionate, more than acetate, elicit a specific change of response by human 
DCs; further, butyrate and propionate share the largest number of host 
dendritic cell genes that were affected by SCFAs exposure as well as has 
been showed by Lokovac et al. for the murine gut organoids model (Lukovac, 
Belzer, Pellis, & al., 2014). 
Among these observations we focused on the potential immunomodulatory 
effect exerted by SCFAs on human DCs, previously reported on another type 
of APC cells such as bone marrow-derived macrophages in a murine model  
(Chang, Offermanns, & al., 2014). In fact, it is known that macrophages, 
once activated by LPS- stimuli, have the important role to prime and enhance 
the inflammasome producing large amounts of CCL2, TNF-, IL-12p40 and 
IL-6; has been shown that mainly butyrate suppresses the production of 
those inflammatory mediators by monocytes and macrophages  (Cox, 
Jackson, STanton, & al., 2009)  (Fukae, Amasaki, Yamashita, & al., 2005) 
and further in one study seems to enhance the release of the anti-
inflammatory cytokine IL-10 (Saemann, Bohmig, Osterreicher, & al, 2000). 
Accordingly with these results, we observed that among the SCFAs analyzed, 
only butyrate and propionate, but not acetate, play a crucial role in 
modulating immune responses on human dendritic cells. In particular, in our 
study, propionate shows the ability to reduce IL-6 expression and release, 
more than butyrate and both butyrate and propionate to reduce the 
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expression of IL-12B (IL12p40), a shared component for IL-12 and IL-23 
formation  (Oppmann, Lesley, Blom, & al., 2000). This latter data lets us to 
hypothesize that both SCFAs compromising the right IL-12 and IL-23 
production could shape the T naive polarization reducing the pro-
inflammatory Th1 and Th17 phenotypes and therefore favoring the balance 
towards anti-inflammatory populations such as Tregs, as already shown in 
mice  (Arpaia, Campbell, Fan, & al., 2013). In addition, it also appears that 
the activity of butyrate and propionate are selective because they do not 
affect primary LPS response genes such as TNF- and CCL2.  
Another aspect of our study was to explore how the DCs chemokines pattern 
was influenced by SCFAs taken that the chemokine production is 
instrumental for DCs to regulate their own migratory capacities and to 
organize recruitment of different cell types for both the afferent and efferent 
limb of the immune response (Sallusto, Palermo, Lenig, & al, 1999). It is 
already known, in addition to their chemotactic effect on neutrophils, SCFAs 
also modulate production and release of chemokines and expression of 
adhesion molecules in neutrophils  (Vinolo, Rodrigues, Hatanaka, & al, 2009) 
and endothelial cells  (Miller, Zaloga, Hoggatt, & al, 2005), which may be 
relevant to their effect on leukocytes recruitment. We observed that in the 
first 24h after the exposure to SCFAs each of them showed a peculiar 
individual effect, acetate reduces the release of CCL3, butyrate decreases 
CCL4, CCL5 and CXCL9,-10,-11 and propionate CCL3, CCL5 and CXCL9,-10,-
11 in terms of gene expression and protein production. Early on Sallusto et 
al. has shown that inflammatory chemokines, such as CCL3, CCL4, and CCL5, 
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can be induced during maturation/ activation of human monocyte-derived 
DCs  (Sallusto, Palermo, Lenig, & al, 1999) and, together with the other pro-
inflammatory chemokines CXCL9, CXCL10, CXCL11, our results strongly 
support the idea that SCFAs exert an immunomodulatory effect per se 
directly on DCs. It is likely that inflammatory chemokines regulate cell traffic 
within secondary lymphoid tissues and, thus, it may influence T cell 
development during antigen recognition (Moser & Loetscher, 2001).  
We observed the up-regulation of ALDH1A1 gene in both im-DCs and m-DCs 
after butyrate treatments. Aldh1a1 is an enzyme involved in metabolizing 
retinoic acid that is also produced from Vitamin A and is crucial for the 
development of food-specific Fop3+ Tregs. The expression of Aldh1a1 is  
directly dependent on GPR109a and regulated by butyrate, as already 
observed in butyrate-treated mouse colonic DCs and macrophages  (Singh, 
Gurav, Sivaprakasam, & al, 2014). Our data clarify that among the three 
SCFAs studied, butyrate and propionate exert the main immunomodulatory 
role directly influencing DCs in gene expression profile. These findings open a 
new perspective on the ability of SCFAs to modulate the human m-DCs 
response to an inflammatory stimulus and guide them to a fine regulation of 
leukocyte polarization and recruitment.  
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5.5. III part. Results and discussion 
5.5.1. Lymphocytes subsets circulating in peripheral blood  
 
 
The process of the early immune reconstitution of 23 pediatric patients was 
followed by measuring the kinetic of relapse of the twelve immune system's 
populations circulating in blood one time point before and subsequent after 
the transplantation, from the time of the engraftment (neutrophil and 
platelet engraftment were defined as occurring on the first of the three 
consecutive days on which the neutrophil level was 0.5•109/l or higher and 
the blood platelets were above 20•109/l, respectively) every ten days for 
three months, covering the time of the potential risk of aGvHD onset. 
Some of the children enrolled at the beginning were excluded for lack of 
informed consent, incomplete sample collection, and sample not evaluable 
for technical reasons. 
The challenging nature of the enrollment of all children, for whom parents 
consent and strong motivation required due to obtain compliance for the 
collection of blood samples during a highly sensitive period, limited the 
patients studied in this latter part of the thesis and it should considered one 
of the few ongoing studies about IS reconstitution involving children and 
collecting data among twelve different subsets. 
Absolute counts of different lymphocytes subsets were determined in 
peripheral blood by flow cytometry (FACS CantoII, BD) after staining with 
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monoclonal antibodies for cell surface antigens or intracellular markers; have 
been considered several potential factors affecting the IS's speed of recovery 
including age, type of donor, diagnosis, conditioning, source of stem cells 
that can impact on final reconstitution.  
Considering the small cohort of patients, has been evaluated to split the 
patients only regarding the type of transplantation (MUD vs. SIBLING) and 
the aGvHD onset (aGvHD vs. no-GvHD) for the analysis; in fact, had not 
been possible to consider other factors affecting the speed of the recovery 
because further subdivisions would have been carried out in even smaller 
subgroups not comparable between each other. 
Owing to low total lymphocyte counts in the early phase of immune recovery 
post HSCT, we calculated the absolute counts of lymphocyte subsets and not 
their relative frequencies. 
As expected, each subset has its peculiar trend (Figure 22, Figure 23): 
Natural killer cells (NKs - CD16+CD56+), related to innate immunity, 
usually take 1-2 months to normalize, although NK are the first lymphocyte 
subset to return to a normal level just before 100 days (average cell/ul 
[range cell/ul]) (MUD: 317 [116-646] vs. Sib: 170 [13-437]) especially 
considering the MUD group.  
B cells (pan CD19+), involved in adaptive immunity, are at very low values  
during the first 2 months following transplant and those cells that are 
present are of donor origin; they usually start to be detectable after 3-5 
months and completely reconstitute at least 1-2 year post transplant. 
T helper and cytotoxic cells (CD3+CD4+/CD8+) reconstitution is 
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markedly different than of B cells and it does not mimic ontogeny: 
memory/effector T cells originating from mature T cells present in the graft 
relatively more abundant than naive cells; it might be because the thymus is 
not completely mature in some children and also it can be damaged after the 
conditioning. 
In general, given the lack of naive T cells (both CD4 and CD8), the T cell 
repertoire is limited and furthermore, for unknown reasons, peripheral 
expansion of memory T cells (CD45R0+) is slightly more effective for CD8 
than CD4 considering the late reconstitution, as largely reported; instead, for 
example, looking at day 100 MUD group CD8+ (210[0-588]) vs CD4+ 
(174[64-388]) and no-GvHD group CD8+ (306[50-588]) vs. CD4+ (258[112-
388]) it seems not possible to discriminate a clear predominance of memory 
CD8+ cells than CD4+ underlying that the two population are still 
unbalanced and their reconstitution requires more time to reach normal 
values. 
T helper 1, 2 and 17 cells are very low or undetectable since the 
engraftment and during the first 100 days, their relapse clearly overcomes 
the period considered; in fact for all the four groups that have been 
considered, Th17 and Th2 cells/ul values do not increase during 100 days. 
Regarding the Th1 cells values there is not a strong difference between all 
the four groups: MUD (9[1-17]), Sib (2[0-6], aGvHD (4[1-9]), no-GvHD (7[0-
17]). 
Treg cells are relatively abundant respect the T helper cells 1 and 17, 
confirming their immunomodulatory role. Has been observed a significant 
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difference between aGvHD vs. noGvHD groups at 100 days‟ time point 
(3.5[1.35-5.71] vs. 43[12-99]) (Mann-Whitney test, p value<0.05) that may 
contribute to a better recovery in the patients and prevents the GvHD onset. 
 
In general, the comparison between those two big groups analysis do not 
show a real and substantial difference among the lymphocytes subsets 
trends.  
For each subset comparison, between the four groups considered, has also 
been performed the two-way ANOVA statistical test to assess whether, 
considering all the time points, a better reconstitution was due to the GvHD 
onset or the type of HCT; the analysis revealed that only the GvHD onset has 
a statistic impact (P value<0.05) on all the subset's reconstitutions trends 
but not the type of HSCT. 
Furthermore if we not exclude the pre-transplantation values to the data set, 
the two-way ANOVA test reveals the time as one of the most important 
factor affecting on the reconstitution (p value<0.001); in the other hand, if 
we excluded those values only the factor "GvHD" seemed to affect on each 
trend. This latter observation is reasonable taken that any recovery per se  
requires time especially and considering that the pre-transplantation values, 
healthy-like, consistently increase the difference in average and standard 
deviation respect all the other values following the transplant. 
We also noticed, among the four groups, that splitting our cohort in 
MUD/SIBLING groups leads to even enhance the standard deviation for each 
individual average value (st. dev. not shown in charts) making us think that it 
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is strongly necessary to enroll more patients to reduce the variability, in 
order to deeply analyze the type of transplantation as a influencing factor on 
the early IS's reconstitution. 
Unfortunately, up to date, all the data we obtained did not lead us to extend 
the analysis in order to consider possible any correlation between IS subsets 
with infections and GvHD incidence or post-transplant morbidity and 
mortality. 
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Figure 22: Lymphocytes trends among aGvHD and no GvHD groups. Averages of Absolute 
lymphocyte counts (ALC) are shown and connected by a time-line for 100 days after HSCT. 
Footnotes: T helper cells (CD3+CD4+), Cytotoxic T cells (CD3+CD8+), B cells (pan CD19+), 
naive T cells (CD45RA+ CD3+CD4+/CD8+), memory T cells (CD45R0+CD3+CD4+/CD8+),  
Th1 (CD3+CD4+IFN-), Th2 (CD3+CD4+IL-4+), Th17 (CD3+CD4+IL-17+), Treg 
(CD3+CD4+CD25++CD127-FoxP3+). 
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Figure 23: Lymphocytes trends among MUD and SIBLING groups. Averages of Absolute 
lymphocyte counts (ALC) are shown and connected by a time-line for 100 days after HSCT. 
Footnotes: T helper cells (CD3+CD4+), Cytotoxic T cells (CD3+CD8+), B cells (pan CD19+), 
naive T cells (CD45RA+ CD3+CD4+/CD8+), memory T cells (CD45R0+CD3+CD4+/CD8+),  
Th1 (CD3+CD4+IFN-), Th2 (CD3+CD4+IL-4+), Th17 (CD3+CD4+IL-17+), Treg 
(CD3+CD4+CD25++CD127-FoxP3+).
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5.6. III part: Conclusions 
A rapid immune reconstitution post-HSCT is of central importance to protect 
the patients from relapse and severe infections  (Koel, Bochennek, 
Zimmermann, & al., 2007)  (Kim, Kim, Sohn, & al., 2004)  (Kalwak, 
Gorczynska, Toporski, & al., 2002). An adequate immune recovery can 
effectively eliminate a recipient's residual malignant cells in the early phase 
post SCT, therby reducing the risk of relapse  (Powles, Singhal, Treleaven, & 
al, 1998). Patients with delayed immune reconstitution show an enhanced 
probability of relapse and late infections remain the major cause of non-
relapse mortality  (Fry & Mackall, 2005). In patients with impaired immune 
reconstitution the introduction of additional cell therapies may be helpful to 
augment the immune functions  (Kim, Kim, Sohn, & al., 2004). To date, 
intervention in pediatric patients has mainly based on minimal residual 
disease diagnostic and donor/recipient chimerism  (Bader, Niethammer, 
Willash, & al., 2005).  
This aspect emphasizes the importance of studying the immune system 
reconstitution as a mirror of potential risks of complications that -with the 
appropriate therapies- could be avoided or prevented. 
Adult patients show a very slow immune reconstitution reaching normal 
values 2-3 years post transplantation  (Storek, Dawson, Storer, & al, 2001). 
This is due to the thymus, which rapidly involutes after puberty  (Dumont-
Girard, Roux, van Lier, & al., 1998)  (Roux, Dumont-Girard, Starobinski, & al, 
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2000). In contrast, in children immune reconstitution, cell function and T-cell 
receptor repertoire recover much faster within the first one and half year 
post SCT  (Kook, Goldman, al., & al., 1996)  (Kook, Goldman, Giller, & al., 
1997)  (Kalwak, Gorczynska, Toporski, & al., 2002).  
Among the factors known to influence immune reconstitution are the stem 
cell source, the amount of CD34+ cells and the content of CD3+ cells in the 
graft  (Kook, Goldman, al., & al., 1996)  (Kalwak, Gorczynska, Toporski, & 
al., 2002) (Roux, Dumont-Girard, Starobinski, & al, 2000)  (Fallen, 
McGreavey, Madrigal, & al., 2003), the cytomegalovirus status before and 
after SCT  (Kalwak, Gorczynska, Toporski, & al., 2002)  (Storek, Dawson, 
Storer, & al, 2001)  (Kook, Goldman, Giller, & al., 1997), the relationship and 
disparity between donor and recipient  (Niehues, Rocha, Filipovich, & al., 
2001)  (Kalwak, Moson, Cwian, & al., 2003), the age of patients  (Fallen, 
McGreavey, Madrigal, & al., 2003)  (Kook, Goldman, Giller, & al., 1997), and 
the development of GvHD  (Roux, Dumont-Girard, Starobinski, & al, 2000)  
(Kook, Goldman, Giller, & al., 1997). 
Among all the factors already mentioned above we have considered the type 
of transplantation regarding the disparity between donor and recipient, and 
the development of GvHD; moreover we focused only at the early 
reconstitution, so evaluating the lymphocytes reconstitution during the first 
100 days after the transplantation.   
The limited period of time and the small number of patients enrolled forced 
to do not split further the cohort for subsequent analysis, so the main big 
four groups evaluated were: GvHD vs. no-GvHD and MUD vs. Sibling.  
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From the comparison between GvHD vs. no-GvHD and MUD vs. Sibling we 
observed that there were not real differences in each trends of recovery 
between all four groups suggesting that, up to date, our study is not enough 
abounding in patients in order to allow more analysis and statistical 
discrimination power. 
Neverthless, we observed that each peripheral subset has its own trend and 
even if we have not obtained substancial statistical validation they showed a 
similar tendency already observed in literature. 
We noticed that NK cell counts recover rapidly within 1 month post-
transplantation, followed by cytotoxic CD3+CD8+ T cells 2-3 months and 
CD19+ B cells even after the period considered, as has already been shown 
by  Koel, Bochennek, Zimmermann, & al., 2007. Initially, mostly of the 
cytotoxic T cells are memory CD45R0+CD8+, whereas the naive 
CD45RA+CD8+ regenerate in the second half year post SCT.  
CD3+CD4+ T helper cells emerge very slow reaching normal values 6-10 
months post SCT  (Kook, Goldman, al., & al., 1996)  (Kalwak, Gorczynska, 
Toporski, & al., 2002)  (De Vries, Van Tol, Van der Bergh, & al., 2000)  (Kim, 
Kim, Sohn, & al., 2004)  (Koel, Bochennek, Zimmermann, & al., 2007) and as 
we observed Th1, Th2, Th17 and Treg cells were absent or barely detectable 
during the first 3 months. 
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6. General conclusions 
 
Allogeneic HSCT is a potential curative therapy for children with hematologic 
disorders, primary immunodeficiency and metabolic disease. The main 
complications of HSCT are represented by infections, secondary malignances 
and GVHD, an immunological disorder which can be lethal and limits the use 
of this important procedure. GVHD arises when donor T cells respond to 
genetically defined protein expressed on host cells APC such as DCs.  
Human beings share a close mutualistic relationship with the GM; in 
particular, the interaction with the gut microbiota GM is crucial for a balanced 
immune system development. Indeed, GM regulates the adaptive immune 
response, exerts a key role in the education of the immune system to 
tolerance and influence the functionality of the intestinal epithelium. 
Moreover, GM can impact the host susceptibility to enteropathogen infection 
by exerting the well-known barrier effect.   
As an active component of the human immune system, the GM structure - 
and the resulting pattern of immunological interaction with the host – can be 
of primary importance in governing the fate of the immunological recovery in 
patients who undergoing aHSCT, predisposing or protecting from the aGVHD 
onset.  
Following this hypothesis, by providing the first monitoring of the GM 
changes occurring during the early recovery of immune defenses in children 
undergoing allogeneic HSCT, the GM has been sequenced in ten enrolled 
children.  
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The GM composition‟s analysis have shown a peculiar trajectory of 
reconstruction of the individual microbiota profile after HSCT, which is 
temporary interrupted by the occurrence of GvHD; even though the strong 
clinical pathway (transplantation, pharmacological treatment, fasting, GvHD) 
the gut microbiota from different subjects tends to group with itself and, 
differently, the subject who developed intestinal aGvHD maintains his 
individuality and his distance from the others. For all the patients it has been 
shown that the GM regains its own composition similar to the one showed 
before transplantation.  
We also showed that the pre-HSCT samples of the subjects who did not 
developed GvHD tended to show higher abundance of Bacteroides  and 
Parabacteroides, with respect to the pre-HSCT samples of GvHD patients; 
further, the relative abundances of Bacteroides and Parabacteroides in the 
pre-HSCT samples were found significantly correlated with the amount of the 
immunomodulatory SCFA propionate. Also, pre-HSCT samples in subject who 
did not develop GvHD tended to show higher amounts of both total SCFAs 
and propionate suggesting that SCFAs may exert a protective role versus 
aGvHD onset.  
Our study indicates, with the needed caution, that the pre-existing GM 
structure can be protective against aGvHD onset, and we propose a model in 
which specific gut mutualist microorganisms, belonging to Bacteroidetes 
phylum and able to produce immunomodulatory protective metabolites, 
resist the ecosystem damages by HSCT and can act as founders for the 
ecosystem recovery, preventing the occurrence of future complications.  
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In this scenario we hope that our study emphasizes the importance to seek 
new and less invasive strategies to reduce the probability of aGvHD in 
pediatric patients by manipulating the pre-HSCT dietary habits.  
Taken the difficulty to find a valid biomarkers among the lymphocites subsets 
that might help routinely the clinicians to predict the GvHD onset (or other 
complications) and taken the lack of a statistic correlation between the 
immune system lymphocites's trends and the GM composition probably due 
to the high biological variables between different human beings or to the few 
patients considered in this study, we focused on in vitro experiments trying 
to find out a possible cross-talk or interactions between this two worlds 
considering the bacterial metabolites SCFAs and DCs cells as the main 
characters of this connection.  
We observed that among the SCFAs analyzed, only butyrate and propionate, 
but not acetate, play a crucial role in modulating immune responses on 
human dendritic cells. In particular, in our study, propionate shows the 
ability to reduce IL-6 expression and release more than butyrate does, and 
both butyrate and propionate to reduce the expression of IL-12B (IL12p40), 
a shared component for IL-12 and IL-23 formation. 
We also have demostrated that butyrate and proprionate, more than acetate, 
influence the DCs maturation process affecting the chemokines profile and 
the consequent DCs ability to shape the T cells polarization, that may be the 
way through SCFAs shape the immune system balancing between 
tolerogenic and inflammatory behaviour. 
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At the light of all these findings we think is interesting to emphasize a final 
aspect that might be promising for further studies. As mentioned in the 
second part of this thesis, we noticed a strong immunomodulatory effect 
exherted by both butyrate and propionate on the chemokine release CXCL9, 
CXCL10, CXCL10. Those chemokines were recently pointed as biomarkers of 
chronic GvHD because increased in the serum of patients with chronic skin 
manifestations  (Croudace, Inman, Abbotts, & al., 2012) and especially the 
CXCL10, together with IL-6 and IL12, have been also considered as a 
candidates aGvHD biomarkers with diagnostic and prognostic significance  
(Piper, Horlock, Curnow, & al, 2007)  (Malone, Leisenring, Storer, & al., 
2007)  (Mohty, Blaise, Faucher, & al, 2005). 
These findings together with our observations let us to hypothesize that 
changing the dietary habits of transplanted patients in favour of species that 
produce more immunomodulatory metabolites, such as SCFAs, could be 
useful in order to indirectly protect from the onset or reduce the 
manifestations of the graft-versus host disease. 
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